UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended June 30, 20172018

 

or

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period From ____________ to ____________

 

Commission File Number: 000-54258

 

TERRA TECH CORP.

(Exact Name of Registrant as Specified in its Charter)

 

NEVADA

26-3062661

(State or Other Jurisdiction of Incorporation or Organization)

(I.R.S. Employer Identification No.)

 

2040 Main Street, Suite 225

Irvine, California

92614

(Address of Principal Executive Offices)

(Zip Code)

 

(855) 447-6967

(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

¨

Accelerated filer

x

Non-accelerated filer

¨

Smaller reporting company

¨

Emerging growth company

¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

 

As of August 4, 2017,6, 2018, there were 640,043,03672,189,614 shares of common stock outstanding, 1008 shares of Series A Preferred Stock, convertible at any time into 1008 shares of common stock, 33,146,1120 shares of Series B Preferred Stock, convertible into 178,469,458 shares of common stock, 15,668,2981,092,754 shares of common stock issuable upon the exercise of all of our outstanding warrants and 4,744,687884,207 shares of common stock issuable upon the exercise of all vested stock options.

 

 
 
 

TERRA TECH CORP. AND SUBSIDIARIES

INDEX TO FORM 10-Q FOR THE

QUARTERLY PERIOD ENDED JUNE 30, 20172018

 

INDEX

Page

PART I — FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Consolidated Balance Sheets as of June 30, 20172018 (Unaudited) and December 31, 20162017

3

Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2018 and 2017 and 2016 (Unaudited)

4

Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2018 and 2017 and 2016 (Unaudited)

5

Notes to Unaudited Consolidated Financial Statements for the Three and Six Months Ended June 30, 2017 and 2016

6

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

2631

Company Overview

31

26

Results of Operations

34

Disclosure About Off-Balance Sheet Arrangements

37

38

Critical Accounting Policies and Estimates

37

38

Liquidity and Capital Resources

38

37

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

38

40

 

Item 4.

Controls and Procedures

39

40

 

PART II — OTHER INFORMATION

 

Item 1.

Legal Proceedings

41

 

Item 1A.

Risk Factors

42

41

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

42

41

 

Item 3.

Defaults Upon Senior Securities

42

41

 

Item 4.

Mine Safety Disclosures

42

41

 

Item 5.

Other Information

42

41

Item 6.Exhibits

43

 

Item 6.Signatures

Exhibits

42

44

Signatures

43

 

 
2
 
Table of Contents

 

TERRA TECH CORP. AND SUBSIDIARIES

TERRA TECH CORP. AND SUBSIDIARIES 

 

CONSOLIDATED BALANCE SHEETS 

 

 

 

 

 

 

 

 

June 30,

 

 

December 31, 

 

 

 

2018

 

 

2017

 

 

 

(Unaudited)

 

 

 

ASSETS 

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash

 

$5,153,608

 

 

$5,445,582

 

Accounts Receivable

 

 

1,210,446

 

 

 

959,698

 

Notes Receivable

 

 

6,158,731

 

 

 

5,010,143

 

Inventory

 

 

3,840,773

 

 

 

5,760,019

 

Assets Held for Sale

 

 

904,352

 

 

 

-

 

Prepaid Expenses and Other Current Assets

 

 

1,086,989

 

 

 

1,067,689

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

 

18,354,899

 

 

 

18,243,131

 

 

 

 

 

 

 

 

 

 

Property, Equipment and Leasehold Improvements, Net

 

 

34,940,408

 

 

 

19,191,616

 

Intangible Assets, Net

 

 

26,696,348

 

 

 

27,773,110

 

Goodwill

 

 

28,921,260

 

 

 

28,921,260

 

Other Assets

 

 

878,098

 

 

 

4,058,682

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS 

 

$109,791,013

 

 

$98,187,799

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY 

LIABILITIES: 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts Payable and Accrued Expenses

 

$4,076,973

 

 

$5,444,710

 

Derivative Liabilities

 

 

1,891,400

 

 

 

9,331,400

 

 

 

 

 

 

 

 

 

 

Total Current Liabilities

 

 

5,968,373

 

 

 

14,776,110

 

 

 

 

 

 

 

 

 

 

Long-Term Liabilities:

 

 

 

 

 

 

 

 

Long-Term Debt, Net of Discounts

 

 

12,811,403

 

 

 

6,609,398

 

 

 

 

 

 

 

 

 

 

Total Long-Term Liabilities

 

 

12,811,403

 

 

 

6,609,398

 

 

 

 

 

 

 

 

 

 

Total Liabilities 

 

 

18,779,776

 

 

 

21,385,508

 

 

 

 

 

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY: 

 

 

 

 

 

 

 

 

Preferred Stock, Convertible Series A, Par Value 0.001:

 

 

-

 

 

 

-

 

100 Shares Authorized as of June 30, 2018 and December 31, 2017; 8 Shares Issued and Outstanding as of June 30, 2018 and December 31, 2017

Preferred Stock, Convertible Series B, Par Value 0.001:

 

 

-

 

 

 

-

 

49,999,900 Shares Authorized as of June 30, 2018 and December 31, 2017; 0 Shares Issued and Outstanding as of June 30, 2018 and December 31, 2017

Common Stock, Par Value 0.001:

 

 

70,853

 

 

 

61,819

 

990,000,000 Shares Authorized as of June 30, 2018 and December 31, 2017; 70,852,978 and 61,818,560 Shares Issued and Outstanding as of June 30, 2018 and December 31, 2017, respectively

Additional Paid-In Capital

 

 

216,839,872

 

 

 

181,357,715

 

Accumulated Deficit

 

 

(127,008,525)

 

 

(105,548,602)

 

 

 

 

 

 

 

 

 

Total Terra Tech Corp. Stockholders’ Equity

 

 

89,902,200

 

 

 

75,870,932

 

Non-Controlling Interest

 

 

1,109,037

 

 

 

931,359

 

 

 

 

 

 

 

 

 

 

Total Stockholders’ Equity 

 

 

91,011,237

 

 

 

76,802,291

 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 

 

$109,791,013

 

 

$98,187,799

 

CONSOLIDATED BALANCE SHEETS

 

 

June 30,

 

 

December 31,

 

 

 

2017

 

 

2016

 

 

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash

 

$9,131,306

 

 

$9,749,572

 

Accounts Receivable

 

 

784,071

 

 

 

747,792

 

Inventory

 

 

3,233,072

 

 

 

1,909,330

 

Prepaid Expenses

 

 

1,238,529

 

 

 

704,721

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

 

14,386,978

 

 

 

13,111,415

 

 

 

 

 

 

 

 

 

 

Property, Equipment and Leasehold Improvements, Net

 

 

10,581,265

 

 

 

10,464,764

 

Intangible Assets, Net

 

 

22,768,048

 

 

 

23,627,098

 

Goodwill

 

 

28,921,260

 

 

 

28,921,260

 

Other Assets

 

 

221,118

 

 

 

54,193

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$76,878,669

 

 

$76,178,730

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

LIABILITIES:

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts Payable and Accrued Expenses

 

$3,526,498

 

 

$2,417,400

 

Derivative Liabilities

 

 

3,163,000

 

 

 

6,987,000

 

Short-Term Debt

 

 

575,705

 

 

 

564,324

 

Income Taxes Payable

 

 

615,830

 

 

 

615,830

 

Contingent Consideration

 

 

 

 

 

12,085,859

 

 

 

 

 

 

 

 

 

 

Total Current Liabilities

 

 

7,881,033

 

 

 

22,670,413

 

 

 

 

 

 

 

 

 

 

Long-Term Liabilities:

 

 

 

 

 

 

 

 

Long-Term Debt

 

 

736,290

 

 

 

1,354,352

 

 

 

 

 

 

 

 

 

 

Total Long-Term Liabilities

 

 

736,290

 

 

 

1,354,352

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

8,617,323

 

 

 

24,024,765

 

 

 

 

 

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

STOCKHOLDERS’ EQUITY:

 

 

 

 

 

 

 

 

Preferred Stock, Convertible Series A, Par Value $0.001:

100 Shares Authorized as of June 30, 2017 and December 31, 2016;
100 Shares Issued and Outstanding as of June 30, 2017 and December 31, 2016

 

 

 

 

 

 

Preferred Stock, Convertible Series B, Par Value $0.001:

49,999,900 Shares Authorized as of June 30, 2017 and December 31, 2016;
33,146,112 and 36,825,953 Shares Issued and Outstanding as of June 30, 2017 and December 31, 2016, respectively

 

 

33,146

 

 

 

36,826

 

Common Stock, Par Value $0.001:

990,000,000 Shares Authorized as of June 30, 2017 and December 31, 2016;
618,667,265 and 553,863,812 Shares Issued and Outstanding as of June 30, 2017 and December 31, 2016, respectively

 

 

618,667

 

 

 

553,864

 

Additional Paid-In Capital

 

 

152,354,775

 

 

 

124,915,182

 

Accumulated Deficit

 

 

(83,436,756)

 

 

(72,870,999)

 

 

 

 

 

 

 

 

 

Total Terra Tech Corp. Stockholders’ Equity

 

 

69,569,832

 

 

 

52,634,873

 

Non-Controlling Interest

 

 

(1,308,486)

 

 

(480,908)

 

 

 

 

 

 

 

 

 

Total Stockholders’ Equity

 

 

68,261,346

 

 

 

52,153,965

 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

 

$76,878,669

 

 

$76,178,730

 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

 
3
 
Table of Contents

 

TERRA TECH CORP. AND SUBSIDIARIES

TERRA TECH CORP. AND SUBSIDIARIES 

CONSOLIDATED STATEMENTS OF OPERATIONS 

(UNAUDITED)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$8,718,177

 

 

$7,842,873

 

 

$17,333,543

 

 

$14,667,329

 

Cost of Goods Sold

 

 

6,509,754

 

 

 

6,336,500

 

 

 

13,477,680

 

 

 

12,801,893

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

2,208,423

 

 

 

1,506,373

 

 

 

3,855,863

 

 

 

1,865,436

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

8,002,370

 

 

 

6,029,287

 

 

 

16,424,918

 

 

 

12,415,587

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(5,793,947)

 

 

(4,522,914)

 

 

(12,569,055)

 

 

(10,550,151)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

(417,363)

 

 

(515,654)

 

 

(885,680)

 

 

(1,126,270)

Loss on Extinguishment of Debt

 

 

(3,127,477)

 

 

(1,639,137)

 

 

(7,858,723)

 

 

(2,678,595)

Gain (Loss) on Fair Market Valuation of Derivatives

 

 

(1,653,000)

 

 

987,200

 

 

 

628,000

 

 

 

2,597,950

 

Interest Expense, Net

 

 

(331,379)

 

 

(130,510)

 

 

(591,000)

 

 

(288,343)

Loss on Fair Market Valuation of Contingent Consideration

 

 

-

 

 

 

(77,286)

 

 

-

 

 

 

(4,426,047)

Gain on Settlement of Contingent Consideration

 

 

-

 

 

 

4,991,571

 

 

 

-

 

 

 

4,991,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

(5,529,219)

 

 

3,616,184

 

 

 

(8,707,403)

 

 

(929,734)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

 

(11,323,166)

 

 

(906,730)

 

 

(21,276,458)

 

 

(11,479,885)
Net Income (Loss) Attributable to Non-Controlling Interest

 

 

104,837

 

 

 

(452,961)

 

 

183,465

 

 

 

(914,128)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO TERRA TECH CORP.

 

$(11,428,003)

 

$(453,769)

 

$(21,459,923)

 

$(10,565,757)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Per Common Share Attributable to Terra Tech Corp. Common Stockholders – Basic and Diluted

 

$(0.17)

 

$(0.01)

 

$(0.32)

 

$(0.28)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-Average Number of Common Shares Outstanding – Basic and Diluted

 

 

68,734,997

 

 

 

38,873,092

 

 

 

66,734,450

 

 

 

38,349,946

 

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

 

 

For the Three Months Ended

 

 

For the Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$7,842,873

 

 

$9,699,909

 

 

$14,667,329

 

 

$11,248,076

 

Cost of Goods Sold

 

 

6,336,500

 

 

 

8,152,935

 

 

 

12,801,893

 

 

 

9,686,575

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

1,506,373

 

 

 

1,546,974

 

 

 

1,865,436

 

 

 

1,561,501

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

6,029,287

 

 

 

5,364,351

 

 

 

12,415,587

 

 

 

7,291,252

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(4,522,914)

 

 

(3,817,377)

 

 

(10,550,151)

 

 

(5,729,751)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

(515,654)

 

 

(218,126)

 

 

(1,126,270)

 

 

(312,532)

Loss on Extinguishment of Debt

 

 

(1,639,137)

 

 

 

 

 

(2,678,595)

 

 

(920,797)

Loss from Derivatives Issued with Debt Greater than Debt Carrying Value

 

 

 

 

 

(488,000)

 

 

 

 

 

(488,000)

Gain (Loss) on Fair Market Valuation of Derivatives

 

 

987,200

 

 

 

(206,000)

 

 

2,597,950

 

 

 

(1,366,700)

Interest Expense

 

 

(130,510)

 

 

(60,565)

 

 

(288,343)

 

 

(116,560)

Loss on Fair Market Valuation of Contingent Consideration

 

 

(77,286)

 

 

 

 

 

(4,426,047)

 

 

 

Gain on Settlement of Contingent Consideration

 

 

4,991,571

 

 

 

 

 

 

4,991,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

3,616,184

 

 

 

(972,691)

 

 

(929,734)

 

 

(3,204,589)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

 

(906,730)

 

 

(4,790,068)

 

 

(11,479,885)

 

 

(8,934,340)

Provision for Income Taxes

 

 

 

 

 

381,000

 

 

 

 

 

 

381,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS

 

 

(906,730)

 

 

(5,171,068)

 

 

(11,479,885)

 

 

(9,315,340)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Attributable to Non-Controlling Interests

 

 

452,961

 

 

 

236,830

 

 

 

914,128

 

 

 

255,038

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO TERRA TECH CORP.

 

$(453,769)

 

$(4,934,238)

 

$(10,565,757)

 

$(9,060,302)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Per Common Share Attributable to Terra Tech Corp. Common Stockholders – Basic and Diluted

 

$

 

 

$(0.01)

 

$(0.02)

 

$(0.03)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-Average Number of Common Shares Outstanding – Basic and Diluted

 

 

583,096,376

 

 

 

349,893,516

 

 

 

575,249,192

 

 

 

338,187,946

 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

 
4
 
Table of Contents

 

TERRA TECH CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

TERRA TECH CORP. AND SUBSIDIARIES

TERRA TECH CORP. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(UNAUDITED)

 

 

 

 

 

 

For the Six Months Ended

June 30,

 

 

Six Months Ended

 

 

2017

 

2016

 

 

June 30,

 

 

 

 

 

 

 

2018

 

2017

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$(11,479,885)

 

$(9,315,340)

 

$(21,276,458)

 

$(11,479,885)

Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:

 

 

 

 

 

 

 

 

 

 

(Gain) Loss on Fair Market Valuation of Derivatives

 

(2,597,950)

 

1,366,700

 

Gain on Fair Market Valuation of Derivatives

 

(628,000)

 

(2,597,950)

Loss on Fair Market Valuation of Contingent Consideration

 

4,426,047

 

 

 

-

 

4,426,047

 

Cancellation of shares issued

 

(117,831)

 

-

 

Gain on Settlement of Contingent Consideration

 

(4,991,571)

 

 

 

-

 

(4,991,571)

Loss on Extinguishment of Debt

 

2,678,595

 

920,797

 

 

7,858,723

 

2,678,595

 

Amortization of Debt Discount

 

1,126,270

 

312,532

 

 

885,680

 

1,126,270

 

Deferred Tax Expense

 

 

49,000

 

Interest Income Accreted

 

(136,877)

 

-

 

Depreciation and Amortization

 

1,778,782

 

787,178

 

 

2,147,499

 

1,778,782

 

Warrants Issued with Common Stock and Debt

 

211,534

 

 

 

-

 

211,534

 

Stock Issued for Compensation

 

1,356,138

 

 

 

552,992

 

1,356,138

 

Stock Issued for Director Fees

 

221,973

 

60,550

 

 

-

 

221,973

 

Stock Issued for Services

 

591,359

 

20,727

 

 

123,727

 

591,359

 

Stock Option Expense

 

205,019

 

95,177

 

Equity Instruments Issued with Debt Greater than Debt Carrying Value

 

 

488,000

 

Change in Allowance for Doubtful Accounts

 

 

102,253

 

Stock Option Compensation

 

954,698

 

205,019

 

Changes in Operating Assets and Liabilities:

 

 

 

 

 

 

 

 

 

 

Accounts Receivable

 

(36,279)

 

(369,557)

 

(250,748)

 

(36,279)

Inventory

 

(1,323,742)

 

(472,970)

 

1,879,923

 

(1,323,742)

Prepaid Expenses

 

(533,808)

 

257,238

 

Prepaid Expenses and Other Current Assets

 

(572,072)

 

(533,808)

Other Assets

 

(166,925)

 

 

 

(120,191)

 

(166,925)

Accounts Payable and Accrued Expenses

 

 

1,383,860

 

 

2,393,183

 

 

 

(1,174,458)

 

 

1,383,860

 

 

 

 

 

 

 

 

 

 

 

NET CASH USED IN OPERATING ACTIVITIES

 

 

(7,150,583)

 

 

(3,304,532)

 

 

(9,873,393)

 

 

(7,150,583)

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Cash Assumed in Acquisition

 

 

163,566

 

Issuance of Note Receivable

 

(1,011,711)

 

-

 

Purchase of Property, Equipment and Leasehold Improvements

 

(1,036,233)

 

(1,988,587)

 

 

(7,447,564)

 

 

(1,036,233)

Purchase of Intangible Assets – Domain Names

 

 

 

 

(75,000)

 

 

 

 

 

 

 

 

 

 

NET CASH USED IN INVESTING ACTIVITIES

 

 

(1,036,233)

 

 

(1,900,021)

 

 

(8,459,275)

 

 

(1,036,233)

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Proceeds from Issuance of Notes Payable

 

6,000,000

 

3,250,000

 

 

15,000,000

 

6,000,000

 

Cash Paid for Debt Discount

 

(180,000)

 

 

 

(645,000)

 

(180,000)

Proceeds from Issuance of Common Stock

 

3,750,000

 

3,208,134

 

Proceeds from Issuance of Common Stock, Warrants and Common Stock Subscribed

 

3,650,000

 

3,750,000

 

Payment of Contingent Consideration

 

(2,088,000)

 

 

 

-

 

(2,088,000)

Cash Contribution from Non-Controlling Interest

 

 

86,550

 

 

 

Proceeds from Exercise of Warrants

 

76,000

 

-

 

Cash (Distribution) Contribution from Non-Controlling Interest

 

 

(5,787)

 

 

86,550

 

 

 

 

 

 

 

 

 

 

 

NET CASH PROVIDED BY FINANCING ACTIVITIES

 

 

7,568,550

 

 

6,458,134

 

 

 

18,075,213

 

 

7,568,550

 

 

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH

 

(618,266)

 

1,253,581

 

 

(257,455)

 

(618,266)

NET CHANGE IN CASH CLASSIFIED WITHIN CURRENT ASSETS HELD FOR SALE

 

(34,519)

 

-

 

Cash at Beginning of Period

 

 

9,749,572

 

 

418,082

 

 

 

5,445,582

 

 

9,749,572

 

 

 

 

 

 

 

 

 

 

 

CASH AT END OF PERIOD

 

$9,131,306

 

$1,671,663

 

 

$5,153,608

 

$9,131,306

 

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE FOR OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Cash Paid for Interest

 

$

 

$10,100

 

 

$428,334

 

$-

 

 

 

 

 

 

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE FOR NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

Settlement of Contingent Consideration

 

$4,739,638

 

$

 

 

$-

 

$4,739,638

 

Purchase of Land and Building with a Mortgage

 

$6,500,000

 

$-

 

Gain on Settlement of Contingent Consideration Recorded Against Additional Paid-In Capital

 

$4,692,697

 

$

 

 

$-

 

$4,692,697

 

Fair Value of Debt Discount Recorded

 

$4,446,000

 

$2,824,000

 

Fair Value of Debt Discount and Derivative Liability Recorded

 

$8,760,000

 

$4,446,000

 

Issuance of Common Stock for Debt and Interest Expense

 

$8,564,324

 

$

 

 

$29,926,761

 

$8,564,324

 

Claw back of Escrow Shares From The Tech Center Drive Asset Acquisition

 

$351,072

 

$-

 

Issuance of Common Stock for Other Assets

 

$200,000

 

$-

 

Fair Value of Warrants Issued for Debt Discount

 

$475,916

 

$-

 

Deposits Applied to the Purchase of Property

 

$3,500,000

 

$-

 

Assets Classified as Held for Sale

 

$904,352

 

 

$-

 

 

The accompanying notes are an integral part of the unaudited consolidated financial statements.

 

 
5
 
Table of Contents

 

TERRA TECH CORP. AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

THREE AND SIX MONTHS ENDED JUNE 30, 2017 AND 2016

 

NOTE 1 – DESCRIPTION OF BUSINESS

 

Organization

 

References in the Notes to Unaudited Consolidated Financial Statementsthis document to “the Company”, “Terra Tech”, “we”, “us”, or “our” are intended to mean Terra Tech Corp., individually, or as the context requires, collectively with its subsidiaries on a consolidated basis.

 

Through MediFarm, LLC, a Nevada limited liability company (“MediFarm”), MediFarm I, LLC, a Nevada limited liability company (“MediFarm I”), and MediFarm II, LLC, a Nevada limited liability company (“MediFarm II”), subsidiaries in which the Company owns interests, the Company operates and/or plans to operate medical marijuana dispensary facilities, cultivation, and production facilities in Nevada. Through IVXX, LLC, a Nevada limited liability company (“IVXX LLC”), and IVXX, Inc., a California corporation (“IVXX Inc.”; together with IVXX LLC, “IVXX”), the Company’s wholly-owned subsidiary, the Company produces and sells a line of cannabis flowers, as well as a line of cannabis pure concentrates. Most recently, the Company formed another subsidiary, MediFarm I Real Estate, LLC, a Nevada limited liability company (“MediFarm I RE”), which owns the real property on which a medical marijuana dispensary will be constructed. The dispensary will be operated by MediFarm I. Through Black Oak Gallery, a California corporation (“Black Oak”), we operate a medical marijuana retail dispensary, a medical marijuana cultivation facility, and have a second medical marijuana cultivation facility in the early stages of construction, all in Oakland, California. The Company is a wholesale sellervertically integrated retail, production and cultivation company, with an emphasis on providing the highest quality of locallymedical and adult use cannabis products. The Company also holds an exclusive patent on an organic antioxidant rich Superleaf lettuce and sells living herbs that are grown using classic Dutch hydroponic produce, herbsfarming methods.

The Company has a presence in three states (California, Nevada and floralNew Jersey), and currently has cannabis operations in California and Nevada. All the Company’s cannabis dispensaries operate under the name Blüm. The Company’s cannabis dispensaries offer a broad selection of medical and adult use cannabis products through its wholly-owned subsidiary, Edible Garden Corp., a Nevada corporation (“Edible Garden”).including flowers, concentrates and edibles.

 

On April 1, 2016,March 12, 2018, the Company acquired Black Oak. Black Oak operatesimplemented a medical marijuana retail dispensary1-for-15 reverse stock split of the Company’s common stock (the “Reverse Stock Split”). The Reverse Stock Split became effective in Oakland, California under the name Blüm, pursuantstock market upon commencement of trading on March 13, 2018. As a result of the Reverse Stock Split, every fifteen shares of the Company’s Pre-Reverse Stock Split common stock were combined and reclassified into one share of the Company’s common stock. The number of shares of common stock subject to that certain Agreementoutstanding options, warrants and Planconvertible securities were also reduced by a factor of Merger, dated December 23, 2015 (the “Merger Agreement”), with Generic Merger Sub, Inc., a California corporationfifteen as of March 13, 2018. All historical share and our wholly-owned subsidiary, and Black Oak.

Since the Merger was completed on April 1, 2016, Black Oak’s financial results are included in ourper share amounts reflected throughout unaudited consolidated financial statements subsequenthave been adjusted to that date.reflect the Reverse Stock Split. The authorized number of shares and the par value per share of the Company’s common stock were not affected by the Reverse Stock Split.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying interim unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles generally accepted in the United States(“GAAP”) for interim financial information and with the instructions to Securities Exchange Commission (“SEC”) Form 10-Q and Article 10 of Regulation S-X. Accordingly, theyS-X of the Securities Act of 1933 and reflect the accounts and operations of the Company and those entities in which we have a controlling financial interest. In accordance with the provisions of FASB or ASC 810, “Consolidation”, we consolidate any variable interest entity (“VIE”), of which we are the primary beneficiary. The typical condition for a controlling financial interest ownership is holding a majority of the voting interests of an entity; however, a controlling financial interest may also exist in entities, such as VIEs, through arrangements that do not involve controlling voting interests. ASC 810 requires a variable interest holder to consolidate a VIE if that party has the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. We do not consolidate a VIE in which we have a majority ownership interest when we are not considered the primary beneficiary. We have determined that we are the primary beneficiary of certain VIEs. We evaluate our relationships with all the VIEs on an ongoing basis to reassess if we continue to be the primary beneficiary.

6
Table of Contents

All intercompany accounts and transactions have been eliminated in consolidation. The accompanying interim unaudited consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principlesGAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. Operatingof the unaudited consolidated financial position of the Company as of June 30, 2018, the unaudited consolidated results of operations for the three and six months ended June 30, 2018 and 2017, are not necessarily indicativeand the unaudited consolidated results of the results that may be expectedcash flows for the year ending December 31, 2017.

The consolidated balance sheet at December 31, 2016 hasthree and six months ended June 30, 2018 and 2017 have been derived from the auditedincluded. These interim unaudited consolidated financial statements at that date but doesdo not include all of the information and footnotes required by generally accepted accounting principlesGAAP for complete financial statements. For further information, refer tostatements and, therefore, should be read in conjunction with the consolidated financial statements and footnotes theretorelated notes contained in the Company’s most recent Annual Report on Form 10-K filed with the SEC. The December 31, 2017 balances reported herein are derived from the audited consolidated financial statements included in Terra Tech’s annual reportthe Company’s Annual Report on Form 10-K for the year ended December 31, 2016.

6
Table of Contents

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)2017, filed with the SEC on March 16, 2018. The results for the interim periods are not necessarily indicative of results to be expected for the full year.

 

Non-Controlling Interest

 

Non-controlling interest is shown as a component of shareholders’stockholders’ equity on the consolidated balance sheets and the share of net income (loss) attributable to non-controlling interest is shown as a component of net income (loss) in the consolidated statements of operations.

 

Use of Estimates

 

The preparation of financial statements in conformityaccordance with United States generally accepted accounting principlesGAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as ofat the datedates of the financial statements and the reported amounts of revenuestotal net revenue and expenses duringin the reporting period. Actualperiods. The Company regularly evaluates estimates and assumptions related to revenue recognition, allowances for doubtful accounts, sales returns, inventory valuation, stock-based compensation expense, goodwill and purchased intangible asset valuations, derivative liabilities, deferred income tax asset valuation allowances, uncertain tax positions, tax contingencies, litigation and other loss contingencies. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results couldof which form the basis for making judgments about the carrying values of assets and liabilities and the recording of revenue, costs and expenses that are not readily apparent from other sources. The actual results the Company experiences may differ materially and adversely from thosethese estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. The Company continues to evaluate the impact of adult use legalization in California on its sales forecasts. Certain of the Company’s assets, such as goodwill, may be negatively impacted if the Company were to decrease its California sales forecasts.

 

Reclassifications

 

Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications did not affect net loss and shareholders’or stockholders’ equity.

 

InventoryAssets Held for Sale

 

We value our inventoryAssets held for sale represent furniture, equipment, and leasehold improvements less accumulated depreciation as well as any other assets that are held for sale in conjunction with the sale of a business. The Company recorded assets held for sale in accordance with ASC 360, “Property, Plant, and Equipment,” at the lower of the actualcarrying value or fair value less cost of our inventory, as determined using the first-in, first-out method, or its current estimated net realizableto sell. Fair value (“NRV”). ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory”, defines NRV as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. We periodically review our physical inventory for excess, obsolete, and potentially impaired items and reserve accordingly. Our reserve estimate for excess and obsolete is based on expected future use. Our reserve estimates have historically been consistent with our actual experience as evidenced by actualthe estimated proceeds from the sale or disposal of the goods.

facility utilizing recent purchase offers, market comparables and/or data. Our estimate as to fair value is regularly reviewed and subject to changes in the commercial real estate markets and our continuing evaluation as to the facility’s acceptable sale price. The reclassification takes place when the assets are available for immediate sale and the sale is highly probable. These conditions are usually met as from the date on which a letter of intent or agreement to sell is ready for signing.

 

Prepaid Expenses

Prepaid expenses consist of various payments that the Company has made in advance for goods or services to be received in the future. These prepaid expenses include advertising, insurance and service contracts requiring up-front payments.

Property, Equipment and Leasehold Improvements

Property, equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The approximate useful lives for depreciation of our property, equipment and leasehold improvements are as follows: 32 years for buildings; three to eight years for furniture and equipment; and the shorter of the estimated useful life or the underlying lease term for leasehold improvements. Repairs and maintenance expenditures that do not extend the useful lives of related assets are expensed as incurred.

Goodwill

Goodwill is measured as the excess of consideration transferred and the net of the acquisition date fair value of assets acquired and liabilities assumed in a business acquisition. Goodwill is not amortized for accounting purposes.

 
7
 
Table of Contents

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

We review the goodwill allocated to each of our reporting units for possible impairment annually as of August 1 and whenever events or changes in circumstances indicate its carrying amount may not be recoverable. When assessing goodwill for impairment, we have the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, we determine it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then we perform a two-step impairment test. If we conclude otherwise, then no further action is taken. We also have the option to bypass the qualitative assessment and only perform a quantitative assessment, which is the first step of the two-step impairment test. In the two-step impairment test, we measure the recoverability of goodwill by comparing a reporting unit’s carrying amount, including goodwill, to the estimated fair value of the reporting unit.

Intangibles

Intangible assets are stated at historical cost and amortized over their estimated useful lives. We use a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined. The approximate useful lives for amortization of our intangible assets are as follows:

Customer Relationships

5 to 12 Years

Trade Names

2 to 8 Years

Dispensary License

14 Years

Patent

2 Years

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. Intangible assets that have indefinite useful lives are tested annually for impairment, and are tested for impairment more frequently if events and circumstances indicate that the asset might be impaired. An impairment loss is recognized to the extent that the carrying amount of the reporting unit exceeds its fair value.

Impairment of Long-Lived Assets

We have adopted paragraph 360-10-35-17 of FASB Accounting Standards Codification (“ASC”) for our long-lived assets. Our long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. We assess the recoverability of our long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the assets expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives.

Other Assets

Other assets are comprised primarily of security deposits for leased properties in California, Nevada and New Jersey. The deposits will be returned at the end of the lease term.

8
Table of Contents

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

Revenue Recognition

 

We recognize revenue in accordance with ASC 605,On January 1, 2018, the Company adopted Accounting Standards Update (ASU) 2014-09, “Revenue Recognition”,from Contracts with Customers” by recognizing as revenueand all the fees we charge customers because persuasive evidencerelated amendments, which are also codified into Accounting Standards Codification (ASC) 606. The Company elected to adopt this guidance using the modified retrospective method. The adoption of an arrangement exists,this standard did not have a material impact on the fees we charge are substantially fixedCompany’s financial position or determinable duringresults of operations. The Company did not restate prior period information for the period that we provide the goods or services, we and our customers understand the specific nature and termseffects of the agreed upon transactions, and payment is madenew standard, nor did the Company adjust the opening balance of its’ retained deficit to account for the goods or services when theyimplementation of the new requirements of this standard. The Company does not expect the adoption of this guidance to have been rendered.a material effect on its’ results of operations in future periods.

Under the new standard, the Company recognizes a sale as follows:

 

Cannabis Dispensary, Cultivation and Production

 

We recognizeThe Company recognizes revenue from manufacturing and distribution product sales and upon transferwhen our customers obtain control of title and risk toour products. Revenue from our retail dispensaries is recorded at the customer, which occurs either at shipping (F.O.B. terms), or upon sell through, depending ontime customers take possession of the arrangement.

product. Revenue from our retail dispensaries is recognized net of discounts, rebates, promotional adjustments, price adjustments and returns, and net of taxes collected from customers that are remitted to governmental authorities, with the collected taxes recorded as current liabilities until remitted to the relevant government authority. Revenue is recorded upon transfer of title and risk to the customer, which occurs at the time customers take delivery of our products at our retail dispensaries. Upon purchase, we havethe Company has no further performance obligations and collection is assured as sales are paid for at time of purchase.

 

Revenue related to distribution customers is recorded when the salecustomer is determined to have taken control of consignment inventorythe product. That determination is based on the customer specific terms of the arrangement and gives consideration to factors including, but not recognizedlimited to, whether the customer has an unconditional obligation to pay, whether a time period or event is specified in the arrangement and whether the Company can mandate the return or transfer of the products. Recorded revenue is net of any discounts, rebates, promotional adjustments and returns, and net of taxes collected from customers that are remitted to governmental authorities, with the collected taxes recorded as current liabilities until the product is pulled from inventory and sold directly to end-customers. We recognize revenue from the sale of consignment inventory on a gross basis, as we have determined that: 1) we are the primary obligorremitted to the customer; 2) we have latitude in establishing the sales prices and profit margins of our products; 3) we have discretion in selecting our suppliers; 4) we are responsible for loss or damage to consigned inventory; and 5) our customer validation process performs an important part of the process of providing such products to authorized customers. We believe that these factors outweigh the fact that we do not have title to the consigned inventory prior to its sale.relevant government authority.

 

Herbs and Produce Products

 

We recognizeThe Company recognizes revenue from products grown in ourits greenhouses and sold net of discounts, rebates, promotional adjustments, price adjustments, andvariable consideration such as estimated returns and upon transferdelivery of title and riskthe product to the customer at which occurs at shipping (F.O.B. terms).time control passes to the customer. Upon shipment, we havetransfer of control, the Company has no further performance obligations, selling price is fixed, and collection is reasonably assured.obligations.

 

CostFor sales for which the Company uses an outside grower, the Company evaluates whether it is appropriate to record the gross amount of Goods Sold

Cannabis Dispensary, Cultivation and Production

Cost of goods sold includes the costs directly attributable to product sales and includes amounts paid for finishedrelated costs or the net amount earned as commissions. The evaluation considers whether the Company takes control of the products of the outside grower, whether it has the ability to direct the outside grower to provide the product to the customer on its behalf or whether it combines products from the outside grower with its own goods such as flower, edibles, and concentrates, as well as packaging and other supplies, fees for services and processing, other expenses for services, and allocated overhead. Overhead expenses include allocations of rent, administrative salaries, utilities, and related costs. It also includesto provide the cost incurred in producingproducts to the oils, waxes, shatters, and clears sold by IVXX.customer.

 

HerbsIn evaluating whether it takes control of the products of the outside grower, the Company considers whether it has primary responsibility for fulfilling the promise to provide the products, whether the Company is subject to inventory risk related to the products and Produce Products

Cost of goods sold arewhether it has the ability to set the selling prices for the plants grown, packaging, other supplies and purchased plants that are sold into the retail marketplace by Edible Garden. Other expenses include freight, allocations of rent, repairs and maintenance, and utilities.products.

 
 
98
 
Table of Contents

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

Stock-Based CompensationFair Value of Financial Instruments

 

The Company accounts for its stock-based awards in accordance with ASC Subtopic 718-10, “Compensation”, which requiresapplies fair value measurement on the grant date and recognition of compensation expenseaccounting for all share-based payment awards madefinancial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to employees and directors, including restricted stock awards. For stock options,transfer a liability in an orderly transaction between market participants at the Company estimatesmeasurement date. When determining the fair value using a closed option valuation (Black-Scholes) model. Themeasurements for assets and liabilities that are required to be recorded at fair value, of restricted stock awardsthe Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is basedestimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

Level 1 –Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market pricedata for substantially the full term of the common shares onassets or liabilities.

Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the date of grant. Theasset or liability.

In accordance with the fair value is then expensed overaccounting requirements, companies may choose to measure eligible financial instruments and certain other items at fair value. The Company has elected the requisite service periods of the awards, net of estimated forfeitures, which is generally the performance period and the related amount is recognized in the consolidated statements of operations.fair value option to measure any eligible financial instruments.

 

WarrantsDerivative Financial Instruments

 

ASC 815-40, Contracts in Entity’s Own Equity”Derivatives and Hedging”, requires freestanding contracts that are settled in a company’s own stock, including common stock warrants, to be designated as an equity instrument, asset or a liability. Under the provisions of ASC 815-40, a contract designated as an asset or a liability must be carried at fair value on a company’s balance sheet, with any changes in fair value recorded in the company’s results of operations. A contract designated as an equity instrument must be included within equity, and no fair value adjustments are required from period to period.

 

ASC 815, “Derivatives and Hedging”, requires all derivatives to be recorded on the balance sheet at fair value. Furthermore, ASC 815 precludes contracts issued or held by a reporting entity that are both (1) indexed to its own stock and (2) classified as stockholders’ equity in its statement of financial position from being treated as derivative instruments.

 

ResearchThe Company estimates the fair value of any new derivative liabilities using the Monte Carlo Simulation (“MCS”) technique because it provides for the necessary assumptions and Development

Researchinputs. The MCS technique, which is an option-based model, is a generally accepted valuation technique for valuing embedded conversion features in convertible notes, because it is an open-ended valuation model that embodies all significant assumption types, and development costs are expensed as incurred.

Income Taxes

We provide for income taxes based on enacted tax law and statutory tax rates at which itemsranges of income and expense are expected toassumption inputs that the Company agrees would likely be settledconsidered in our income tax return. Certain items of revenue and expense are reported for Federal income tax purposes in different periods than for financial reporting purposes, thereby resulting in deferred income taxes. Deferred taxes are also recognized for operating losses that are available to offset future taxable income. Valuation allowances are established when necessary to reduce deferred tax assetsconnection with the arms-length negotiation related to the amount expectedtransference of the instrument by market participants. In addition to the typical assumptions in a closed-end option model, such as volatility and a risk-free rate, MCS incorporates assumptions for interest risk, credit risk and redemption behavior. In addition, MCS breaks down the time to expiration into potentially a large population of time intervals and steps. However, there may be realized. We have incurred net operating losses for financial-reportingother circumstances or considerations, other than those addressed herein, that relate to both internal and tax-reporting purposes. At June 30, 2017 and December 31, 2016, such net operating losses were offset entirelyexternal factors that would be considered by a valuation allowance.

The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained,market participants as it relates specifically to the Company recognizesand the largest amountsubject financial instruments. The effects, if any, of tax benefit that is greater than 50% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations.

Loss Per Common Share

In accordance with the provisions of ASC 260, “Earnings Per Share”, net loss per share is computed by dividing net loss by the weighted-average shares of common stock outstanding during the period. During a loss period, the effect of the potential exercise of stock options, warrants, convertible preferred stock, and convertible debt are not considered in the diluted loss per share calculation since the effect wouldthese considerations cannot be anti-dilutive. The results of operations were a net loss for the three and six months ended June 30, 2017 and 2016. Therefore, the basic and diluted weighted-average shares of common stock outstanding were the same for both periods.reasonably measured, quantified or qualified.

 
 
109
 
Table of Contents

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

Fair Value of Financial Instruments

We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities that are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

In accordance with the fair value accounting requirements, companies may choose to measure eligible financial instruments and certain other items at fair value. We have not elected the fair value option for any eligible financial instruments.

Recently Issued Accounting Standards

FASB ASU No. 2018-07 (Topic 718), “Compensation—Stock Compensation: Improvements to Nonemployee Share-Based Payment Accounting”Issued in June 2018, ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The new standard will be effective for the Company on January 1, 2019. Early adoption is permitted. The Company is in the process of evaluating the impact the adoption of this standard will have on its statements and related disclosure.

 

FASB ASU 2017-04 (Topic 350), “Intangibles - Goodwill and Others” – Issued in January 2017, ASU 2017-04 simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit’s goodwill with the carrying amount of that goodwill. ASU 2017-04 is effective for annual periods beginning after December 15, 2019 including interim periods within those periods. We areThe Company is currently evaluating the effect that ASU 2017-04 will have on our consolidated financial statements and related disclosures.

 

FASB ASU 2017-01 (Topic 805), “Business Combinations: Clarifying the Definition of a Business” – Issued in January 2017, ASU 2017-01 revises the definition of a business and provides new guidance in evaluating when a set of transferred assets and activities is a business. This guidance will be effective for the Company in the first fiscal quarter of 2018 on a prospective basis, and early adoption is permitted. The Company does not expect the standard to have a material impact on our consolidated financial statements.

FASB ASU 2016-15, “Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force)” – Issued in August 2016, the amendments in ASU 2016-15 address eight specific cash flow issues and apply to all entities that are required to present a statement of cash flows under ASC Topic 230, “Statement of Cash Flows”. The amendments in ASU 2016-15 are effective for public business entities for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, including adoption during an interim period. The Company has not yet completed the analysis of how adopting this guidance will affect its consolidated financial statements.

11
Table of Contents

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES(Continued)

FASB ASU No. 2016-02 (Topic 842), “Leases” – Issued in February 2016, ASU No. 2016-02 will require entities to recognize right-of-use assets and lease liabilities on the balance sheet for the rights and obligations created by all leases, including operating leases, with terms of more than 12 months. The new standard also requires additional disclosures on the amount, timing, and uncertainty of cash flows arising from leases. These disclosures include qualitative and quantitative information. The new standard will be effective for the Company on January 1, 2019. Early adoption is permitted. The Company is in the process of evaluating the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.

FASB ASU No. 2014-09 (Topic 606), “Revenue from Contracts with Customers” – Issued in May 2014, ASU 2014-09 will require an entity to recognize revenue when it transfers promised goods or services to customers using a five-step model that requires entities to exercise judgment when considering the terms of the contracts. In August 2015, the FASB issued ASU No. 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date”. This amendment defers the effective date of ASU 2014-09 by one year. In March 2016, the FASB issued ASU 2016- 08, “Principal versus Agent Considerations (Reporting Gross versus Net)”, which amends the principal versus agent guidance and clarifies that the analysis must focus on whether the entity has control of the goods or services before they are transferred to the customer. In addition, the FASB issued ASU Nos. 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers” and 2016-12, “Narrow-Scope Improvements and Practical Expedients”, both of which provide additional clarification of certain provisions in Topic 606. These ASC updates are effective for annual reporting periods beginning after December 15, 2017, but early adoption is permitted. Early adoption is permitted only as of annual reporting periods after December 15, 2016. The standard permits the use of either the retrospective or cumulative effect transition method. We are currently in the process of evaluating all revenue streams, accounting policies, practices and reporting to identify and understand any impact on our consolidated financial statements.

 

NOTE 3 – CONCENTRATIONS OF BUSINESS AND CREDIT RISK

 

The Company maintains cash balances in several financial institutions that are insured by the Federal Deposit Insurance Corporation up to certain federal limitations. At times, the Company’s cash balance exceeds these federal limitations.California Licensed Vendors Requirement

 

The Company provides creditsources cannabis products for retail, cultivation and production from various vendors. However, as a result of the new regulations in the normal courseState of businessCalifornia, the Company’s California retail, cultivation and production operations must use vendors licensed by the State effective January 1, 2018. As a result, the Company will be dependent upon the licensed vendors in California to customers located throughoutsupply products as of that date. If the U.S. Company is unable to enter into a relationship with sufficient members of properly licensed vendors, the Company's sales may be impacted. During the three and six months ended June 30, 2018 and 2017, we did not have any concentration of vendors for inventory purchases. However, this may change depending on the number of vendors who receive appropriate licenses to operate in the State of California.

California Phase-In of Laboratory Testing Requirements

The Bureau of Cannabis Control (“BCC”) is the lead agency in developing regulations for medical and adult-use cannabis in California. The BCC is responsible for licensing retailers, distributors, testing labs and microbusinesses. Prior to July 1, 2018, the BCC allowed for a “transition period” in which they allowed exceptions from specific regulatory provisions. However, beginning July 1, 2018, cannabis goods must meet all statutory and regulatory requirements. A licensee can only sell cannabis goods that have been tested by a licensed testing laboratory and have passed all statutory and regulatory testing requirements. In order to be sold, cannabis goods harvested or manufactured prior to January 1, 2018, must be tested by a licensed testing laboratory and must comply with all testing requirements in section 5715 of the BCC’s regulations. Cannabis goods that do not meet all statutory and regulatory requirements must be destroyed in accordance with the rules pertaining to destruction.

10
Table of Contents

The laboratory testing requirements are being phased-in three tiers. Tiers 1, 2 and 3 have compliance deadlines of January 1, 2018, July 1, 2018 and December 31, 2018, respectively. With each phased-in tier there are specific laboratory testing requirements for different types of cannabis products as outlined below:

Phase-In of Required Laboratory Testing

Inhalable Cannabis

Inhalable Cannabis Products

Other Cannabis & Cannabis Products

Tier 1

January 1, 2018

Cannabinoids Testing

x

x

x

Moisture Content Testing

x

Category II Residual Solvents and Processing Chemicals Testing

x

x

Category I Residual Pesticides Testing

x

x

x

Microbial Impurities Testing (A. fumigatus, A. flavus, A. niger, A. terreus)

x

x

Microbial Impurities Testing (Escherichia coli and Salmonella spp.)

x

x

x

Homogeneity Testing of Edible Cannabis Products

x

Tier 2

July 1, 2018

Category I Residual Solvents and Processing Chemicals Testing

x

x

Category II Residual Pesticides Testing

x

x

x

Foreign Material Testing

x

x

x

Tier 3

December 31, 2018

Terpenoids Testing

x

x

x

Mycotoxins Testing

x

x

x

Heavy Metals Testing

x

x

x

Water Activity Testing of Solid or Semi-Solid Edibles

x

x

On June 8, 2018 the BCC issued new guidance regarding the completion of the transition period from an unregulated to regulated state market.  This guidance was provided to issue direction on how licensees should treat inventory from 2017 and 2018, which was not completely compliant with the BCC regulations that commenced on January 1, 2018. One of these components was that, in addition to tier 1 testing, all products must meet tier 2 testing by July 1, 2018 and tier 3 testing by December 31, 2018.  While testing has not been a barrier to product availability for the Company, performs ongoing credit evaluationsit is possible that as the market transitions from tier 2 to tier 3 testing, that products meeting all three tier testing requirements will be limited in nature.  Through industry discussions, the Company believes that cultivators and manufacturers are aware of its customersthe new requirements and maintains allowances for doubtful accounts basedare taking great measures to meet these requirements.  Considering that other states have similar testing requirements, the Company does not expect that these new testing standards will be an actual barrier to product availability. However, the limited number of testing labs licensed by the state to perform all required tier testing may cause a backlog or delay in testing results, which could have an impact on factors surrounding the credit risk of specific customers, historical trends, and other information.product availability.

11
Table of Contents

 

NOTE 4 – INVENTORYASSETS HELD FOR SALE

 

Raw materials consistAs of Edible Garden’s herb product linesJune 30, 2018, there was one asset group in the Cannabis Dispensary, Cultivation and material for IVXX’s line of cannabis pure concentrates. Work-in-progress consists of live plants grown for Edible Garden’s herb product lines and live plants grown at Black Oak. Finished goods consists of IVXX’s line of cannabis packaged productsProduction segment that met the criteria to be soldrecorded as held for sale under ASC 360: (1) Management, having the authority to approve the action, committed to a plan to sell the asset, (2) The asset group was available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such assets, (3) An active program to locate a buyer and other actions required to complete the plan to sell the asset group have been initiated, (4) The sale of the asset group was probable, and transfer of the asset group was expected to qualify for recognition as a completed sale, within one year, (5) The asset group was being actively marketed for sale at a price that is reasonable in relation to its current fair value, and (6) Actions required to complete the plan indicate that it is unlikely that significant changes to the plan will be made or that the plan will be withdrawn. The assets related to this asset group has been classified as held for sale on the Consolidated Balance Sheets. On July 6, 2018, MediFarm LLC, a wholly-owned subsidiary of the Company, entered into dispensaries,an Asset Purchase Agreement (the “Purchase Agreement”) with Exhale Brands Nevada III, LLC (the “Purchaser”) pursuant to which the Company agreed to sell and Edible Garden’s productsthe Purchaser agreed to purchase substantially all of the assets of the Company related to the Company’s dispensary located at 1921 Western Ave., Las Vegas, NV 89102 (the “Business”). The aggregate consideration to be sold via food, drug,paid for the Business is $6,250,000 in cash plus the value of any inventory of the Business on the closing date. The transaction is subject to approval by the Nevada Department of Taxation and mass channels.

is expected to close promptly following receipt of such approval. There is no material relationship between the Company or its affiliates and the Purchaser other than in respect of the transactions contemplated by the Purchase Agreement. The Purchase Agreement contains customary conditions, representations, warranties, indemnities and covenants by, among, and for the benefit of the parties.

 

CostThe components of goods sold is calculated using the average costing method. The Company reviews its inventory periodically to determine NRV. The Company writes down inventory, if required, based on forecasted demand. These factorsassets held for sale are impacted by market and economic conditions, new products introductions, and require estimates that may include uncertain elements.as follows:

 

 

 

June 30, 2018

 

 

 

 

 

 

Cash

 

$34,519

 

Inventory

 

 

199,323

 

Prepaid Expenses and Other Assets 

 

 

41,700

 

Other Assets

 

 

775

 

Property, Equipment and Leasehold Improvements, Net

 

 

628,035

 

 

 

 

 

 

Assets Held for Sale

 

$904,352

 

 
 
12
 
Table of Contents

 

NOTE 45INVENTORYVARIABLE INTEREST ENTITY ARRANGEMENTS

The Company has a shared interest in two entities, MediFarm I and MediFarm I RE, with another investor for the operation of a cultivation operation and dispensary in Nevada. The entities are considered to be VIE’s and the Company is considered to be the primary beneficiary by reference to the power and benefits criterion under ASC 810, (Continued)“Consolidation.” The Company has reviewed the provisions within the operating agreements and other factors which would grant the Company the power to manage and make decisions that affect the operation of these VIEs.

 

As the primary beneficiary of June 30, 2017MediFarm I and December 31, 2016, inventory consistedMediFarm I RE, the Company consolidates the accounts and operations of these entities. All intercompany transactions are eliminated in the following:

 

 

June 30,

2017

 

 

December 31,

2016

 

 

 

 

 

 

 

 

Raw Materials

 

$1,010,401

 

 

$486,119

 

Work-in-Progress

 

 

1,179,647

 

 

 

570,145

 

Finished Goods

 

 

1,043,024

 

 

 

853,066

 

 

 

 

 

 

 

 

 

 

Total Inventory

 

$3,233,072

 

 

$1,909,330

 

NOTE 5 – PROPERTY, EQUIPMENT AND LEASEHOLD IMPROVEMENTSunaudited consolidated financial statements.

 

AsThe aggregate carrying values of June 30, 2017MediFarm I and December 31, 2016, property, equipmentMediFarm I RE assets and leasehold improvements at cost, less accumulated depreciation, consistedliabilities, after elimination of any intercompany transactions and balances, in the following:consolidated balance sheets were as follows (in thousands):

 

 

 

June 30,

2017

 

 

December 31,

2016

 

 

 

 

 

 

 

 

Land and Building

 

$1,454,124

 

 

$1,454,124

 

Furniture and Equipment

 

 

3,376,758

 

 

 

3,141,244

 

Computer Hardware and Software

 

 

438,210

 

 

 

396,479

 

Leasehold Improvements

 

 

8,458,734

 

 

 

7,568,465

 

Construction in Progress

 

 

297,041

 

 

 

459,327

 

 

 

 

 

 

 

 

 

 

Subtotal

 

 

14,024,867

 

 

 

13,019,639

 

Less Accumulated Depreciation

 

 

(3,443,602)

 

 

(2,554,875)

 

 

 

 

 

 

 

 

 

Property, Equipment and Leasehold Improvements, Net

 

$10,581,265

 

 

$10,464,764

 

Depreciation expense related to property, equipment and leasehold improvements for the three months ended June 30, 2017 and 2016 was $456,659 and $222,939, respectively, and for the six months ended June 30, 2017 and 2016 was $919,732 and $373,668, respectively.

 

 

June 30,

 

 

December 31, 

 

 

 

2018

 

 

2017

 

Current Assets:

 

 

 

 

 

 

Cash

 

$251,508

 

 

$409,029

 

Accounts Receivable, Net

 

 

224,259

 

 

 

-

 

Inventory

 

 

582,657

 

 

 

232,231

 

Prepaid Expenses and Other Current Assets

 

 

94,889

 

 

 

302,186

 

Total Current Assets

 

 

1,153,313

 

 

 

943,446

 

Property, Equipment and Leasehold Improvements, Net

 

 

1,890,709

 

 

 

1,965,103

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS 

 

$3,044,022

 

 

$2,908,549

 

 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts Payable and Accrued Expenses

 

$269,843

 

 

$319,853

 

 

 

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

$269,843

 

 

$319,853

 

 

NOTE 6 – INTANGIBLE ASSETSNOTES RECEIVABLE

 

On October 26, 2017, the Company entered into agreements with NuLeaf Sparks Cultivation, LLC and NuLeaf Reno Production, LLC (collectively, “NuLeaf”) to build and operate cultivation and production facilities for our IVXX brand of cannabis products in Nevada. The agreements are subject to approval by the State of Nevada, the City of Sparks and the City of Reno in Nevada. As part of the agreements, the Company made convertible loans at the time of the agreement of $4.5 million in aggregate to the NuLeaf entities bearing an interest rate of 6% per annum. In April 2018, the Company amended the note receivable with NuLeaf to extend the maturity date to August 1, 2018. Upon approval the loans will automatically convert into a 50% ownership in the NuLeaf entities. On June 28, 2018 the Company received approval from the State of Nevada. The remaining required approvals from local authorities were received in July 2018. As a result, the notes receivable balance at June 30, 2017 and December 31, 2016, intangible assets consisted of the following:

 

 

 

 

 

June 30, 2017

December 31, 2016

 

 

 

Estimated Useful Life in Years

 

 

Gross
Carrying Amount

 

 

Accumulated Amortization

 

 

Net

Carrying Value

 

 

Gross
Carrying Amount

 

 

Accumulated Amortization

 

 

Net

Carrying
Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortized Intangible Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Customer Relationships

 

5 to 12

 

 

$8,960,700

 

 

$(1,218,528)

 

$7,742,172

 

 

$8,960,700

 

 

$(780,960)

 

$8,179,740

 

Trade Brands and Patent

 

2 to 8

 

 

 

498,598

 

 

 

(145,757)

 

 

352,841

 

 

 

498,598

 

 

 

(91,061)

 

 

407,537

 

Dispensary License

 

14

 

 

 

10,270,000

 

 

 

(916,965)

 

 

9,353,035

 

 

 

10,270,000

 

 

 

(550,179)

 

 

9,719,821

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Amortized Intangible Assets

 

 

 

 

 

 

19,729,298

 

 

 

(2,281,250)

 

 

17,448,048

 

 

 

19,729,298

 

 

 

(1,422,200)

 

 

18,307,098

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unamortized Intangible Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Trade Name

 

Indefinite

 

 

 

5,320,000

 

 

 

 

 

 

5,320,000

 

 

 

5,320,000

 

 

 

 

 

 

5,320,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Unamortized Intangible Assets

 

 

 

 

 

 

5,320,000

 

 

 

 

 

 

5,320,000

 

 

 

5,320,000

 

 

 

 

 

 

5,320,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Intangible Assets

 

 

 

 

 

$25,049,298

 

 

$(2,281,250)

 

$22,768,048

 

 

$25,049,298

 

 

$(1,422,200)

 

$23,627,098

 

Intangible assets with finite lives are amortized over their estimated useful lives. We recorded amortization expense of $429,525 and $516,8782018 was converted into a 50% ownership interest in NuLeaf in July 2018. See “Note 17 – Subsequent Events” for the three months endedadditional disclosure regarding changes in notes receivable subsequent to June 30, 2017 and 2016, respectively, and $859,050 and $527,498 for the six months ended June 30, 2017 and 2016, respectively.2018.

 
 
13
 
Table of Contents

 

NOTE 7 – ACCOUNTS PAYABLEPROPERTY, EQUIPMENT AND ACCRUED EXPENSESLEASEHOLD IMPROVEMENTS, NET

 

As of June 30, 2017Property, equipment, and December 31, 2016, accounts payable and accrued expenses consistedleasehold improvements, net consists of the following:

 

 

 

June 30,

2017

 

 

December 31,

2016

 

 

 

 

 

 

 

 

Accounts Payable

 

$1,742,666

 

 

$1,986,907

 

Sales Tax Payable

 

 

360,176

 

 

 

122,470

 

Accrued Interest Payable

 

 

110,217

 

 

 

96,633

 

Accrued Expenses

 

 

1,313,439

 

 

 

211,390

 

 

 

 

 

 

 

 

 

 

Total Accounts Payable and Accrued Expenses

 

$3,526,498

 

 

$2,417,400

 

 

 

June 30,

 

 

December 31, 

 

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

Land and Building

 

$19,662,334

 

 

$9,047,201

 

Furniture and Equipment

 

 

3,715,118

 

 

 

3,553,587

 

Computer Hardware and Software

 

 

492,801

 

 

 

486,176

 

Leasehold Improvements

 

 

8,417,236

 

 

 

9,316,665

 

Construction in Progress

 

 

7,594,184

 

 

 

1,204,547

 

 

 

 

 

 

 

 

 

 

Subtotal

 

 

39,881,673

 

 

 

23,608,176

 

Less Accumulated Depreciation

 

 

(4,941,265)

 

 

(4,416,560)

 

 

 

 

 

 

 

 

 

Property, Equipment and Leasehold Improvements, Net 

 

$34,940,408

 

 

$19,191,616

 

Depreciation expense related to property, equipment and leasehold improvements for the three months ended June 30, 2018 and 2017 was $540,167 and $456,659, respectively, and for the six months ended June 30, 2018 and 2017 was $1,070,737 and $919,732, respectively.

 

NOTE 8 – NOTES PAYABLE

 

As of June 30, 2017 and December 31, 2016, notesNotes payable consistedconsists of the following:

 

 

June 30,

2017

 

 

December 31,

2016

 

 

 

 

 

 

 

 

Unsecured promissory demand notes issued to an accredited investor, which bear interest at a rate of 4% per annum. Holder may elect to convert into common stock at $0.75 per share. The remaining balance of the note and accrued interest was converted into common stock in April 2017.

 

$

 

 

$64,324

 

Convertible promissory note dated December 14, 2015, issued to accredited investors, which matured December 13, 2016 and bears interest at a rate of 12% per annum. The holder of the note extended the maturity to December 13, 2017. The conversion price is $0.1211, subject to adjustment.

 

 

500,000

 

 

 

500,000

 

Senior convertible promissory note dated October 28, 2016, issued to accredited investors, which matures April 28, 2018 and bears interest at a rate of 1% per annum. The conversion price is 90% of the average of the lowest three (3) VWAPs for the five (5) consecutive trading days prior to the conversion date. The remaining balance of the note and accrued interest was converted into common stock in January 2017.

 

 

 

 

 

102,582

 

Senior convertible promissory note dated November 1, 2016, issued to accredited investors, which matures May 1, 2018 and bears interest at a rate of 12% per annum. The conversion price is $0.35, subject to adjustment.

 

 

75,705

 

 

 

31,615

 

Senior convertible promissory note dated December 16, 2016, issued to accredited investors, which matures June 16, 2018 and bears interest at a rate of 12% per annum. The conversion price is $0.27, subject to adjustment.

 

 

 

 

 

1,220,155

 

Senior convertible promissory note dated June 23, 2017, issued to accredited investors, which matures December 23, 2018 and bears interest at a rate of 12% per annum. The conversion price is $0.1362, subject to adjustment.

 

 

736,290

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Debt

 

 

1,311,995

 

 

 

1,918,676

 

 

 

 

 

 

 

 

 

 

Less Short-Term Portion

 

 

575,705

 

 

 

564,324

 

 

 

 

 

 

 

 

 

 

Long-Term Portion

 

$736,290

 

 

$1,354,352

 

As of June 30, 2017 and December 31, 2016, total debt was $1,311,995 and $1,918,676, respectively, which included unamortized debt discount of $2,338,005 and $4,295,648, respectively. Senior secured promissory notes are secured by shares of common stock. There was accrued interest payable of $110,217 and $96,633 as of June 30, 2017 and December 31, 2016, respectively.

 

See “Note 16 – Subsequent Events” for additional disclosure regarding changes in notes payable subsequent to June 30, 2017.

 

 

June 30,

 

 

December 31, 

 

 

 

2018

 

 

2017

 

Senior convertible promissory note dated August 21, 2017, issued to accredited investors, which matures February 21, 2019 and bears interest at a rate of 12% per annum. The conversion price is $4.50, subject to adjustment. The balance of the note and accrued interest was converted into common stock in January 2018.

 

$-

 

 

$640,010

 

Senior convertible promissory note dated December 26, 2017, issued to accredited investors, which matures June 26, 2019 and bears interest at a rate of 12% per annum. The conversion price is $4.50, subject to adjustment.  The balance of the note and accrued interest was converted into common stock in January 2018.

 

 

-

 

 

 

1,469,388

 

Promissory note dated November 22, 2017, issued for the purchase of real property.  Matures December 1, 2020, with an option to extend the maturity date 1 year.  The promissory note bears interest at 12.0% for year one and escalates 0.5% per year thereafter up to 13.5%.

 

 

4,500,000

 

 

 

4,500,000

 

Promissory note dated January 18, 2018, issued for the purchase of real property.  The promissory note is collateralized by the land and building purchased and matures February 1, 2021, with an option to extend the maturity date 1 year.  The promissory note bears interest at 12.0% for year one and escalates 0.5% per year thereafter up to 13.0%.  The full principle balance and accrued interest are due at maturity.

 

 

6,189,144

 

 

 

-

 

Senior convertible promissory note dated June 7, 2018, issued to accredited investors under the 2018 Master Securities Purchase and Convertible Promissory Notes Agreement, which matures December 7, 2019 and bears interest at a rate of 7.5% per annum. The conversion price is $4.50, subject to adjustment. 

 

 

2,122,259

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Long-Term Debt, Net of Discounts

 

$12,811,403

 

 

$6,609,398

 

 
 
14
 
Table of Contents

 

NOTE 8Total debt as of June 30, 2018 and December 31, 2017 was $12,811,403 and $6,609,398, respectively, net of unamortized debt discount of $2,188,597 and $4,790,601, respectively. The senior convertible promissory notes are secured by shares of common stock. There was accrued interest payable of $16,250 and $21,767 as of June 30, 2018 and December 31, 2017, respectively. See “Note 17NOTES PAYABLE(Continued)Subsequent Events” for additional disclosure regarding changes in notes payable subsequent to June 30, 2018.

 

Securities Purchase Agreement Dated June 23, 2017 and 12% Senior Convertible Scheduled Maturities of Long-Term Debt

Scheduled maturities of long-term debt, including the unamortized debt discounts of $2,188,597, are as follows:

 

 

 

 

Year Ending December 31,

 

 

 

Six Months Ending

December 2018

 

 

2019

 

 

2020

 

 

2021

 

 

2022

 

 

2023
and thereafter

 

 

Total

 

Total Debt

 

$-

 

 

$2,122,259

 

 

$4,500,000

 

 

$6,189,144

 

 

$-

 

 

$-

 

 

$12,811,403

 

Promissory Note Due December 23, 2018Notes

 

On June 23, 2017,January 18, 2018, the Company entered into a $6,500,000 promissory note for the purchase of land and a building in California with a third-party creditor. As part of the closing of the purchase of land, the Company issued warrants with a value of approximately $164,000 and paid a cash fee of $195,000. The unamortized balance as of June 30, 2018 was $310,857. The warrants and cash fee were recorded as a debt discount. The interest rate for the first year is 12.0% and increases 0.5% per year, up to 13.0%, through 2021. Payments of interest only are due monthly. The full principle balance and accrued interest are due at maturity.

2018 Master Securities Purchase and Convertible Promissory Notes Agreement

In March 2018, the Company entered into the 2018 Master Securities Purchase Agreement with an accredited investor pursuant to which the Company soldsells to the accredited investor a 12%7.5% Senior Convertible Promissory Note due December 23, 2018 (“Note A”)Notes in the principal amounteight traunches of $3,000,000$5,000,000, for a purchase pricetotal of $3,000,000 (“Offering A”). There were no fees or expenses deducted from the net proceeds received by the Company in Offering A. Note A and the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) issuable upon conversion of Note A are collectively referred to herein as the “Securities.”$40,000,000.

 

AllFor each note issued under the 2018 Master Securities Purchase Agreement, the principal and interest due and owingowed under Note Athe note is convertible into shares of Common Stock at any time at the election of the holder at a conversion price per share equal to the lower of (i) $0.1362the original conversion price as defined in each note issuance or (ii) 85%87% of the average of the two lowest daily volume weighted average price of the Common Stock in the fifteen (15)thirteen (13) trading days prior to the conversion date (“Conversion Price A”Price”), which Conversion Price A is subject to adjustment for (i) stock splits, stock dividends, combinations, or similar events and (ii) full ratchet anti-dilution protection. Upon certain events of default, the conversion price of Note A will automatically become 70% of the average of the three (3) lowest volume weighted average prices of the Common Stock in the twenty (20) consecutive trading days prior to the conversion date for so long as such event of default remains in effect.

 

In addition, at any time that (i) the daily volume weighted average price of the Common Stock for the prior ten (10) consecutive trading days is $0.70$10.50 or more and (ii) the average daily trading value of the Common Stock is greater than $2,500,000 for the prior ten (10) consecutive trading days, then the Company may demand, upon one (1) day’s notice, that the holder convert Note Athe notes at the Conversion Price A.Price.

15
Table of Contents

 

The Company may prepay in cash any portion of the outstanding principal amount of Note Athe notes and any accrued and unpaid interest by, upon ten (10) days’ written notice to the holder, paying an amount equal to (i) 110% of the sum of the then-outstanding principal amount of Note Athe notes plus accrued but unpaid interest, if the prepayment date is within 90 days of the issuance date of Note A;the notes; (ii) 115% of the sum of the then-outstanding principal amount of Note A plus accrued but unpaid interest, if the prepayment date is between 91 days and 180 days of the issuance date of Note A;the notes; or (iii) 125% of the sum of the then-outstanding principal amount of Note Athe notes plus accrued but unpaid interest, if the prepayment date is after 180 days of the issuance date of Note A.the notes.

 

Securities Purchase Agreement Dated February 22, 2017 and 12% Senior Convertible Promissory Note Due August 22,During the period ended March 31, 2018,

On February 22, 2017, the Company enteredissued a 7.5% convertible note for an aggregate value of $5,000,000. In April 2018, the note was converted into a Securities Purchase Agreement with an accredited investor pursuant to whichshares of the Company sold to the accredited investor a 12% Senior Convertible Promissory Note due August 22, 2018 (“Note B”) in the principal amount of $3,000,000 for a purchase price of $3,000,000 (“Offering B”).Company’s common stock. There were no fees or expenses deducted from the net proceeds received by the Company in Offering B. Note Bthe offerings. The Company paid $150,000 in cash and issued approximately $116,000 of warrants in connection with the notes. The cash fee and warrants were recorded as a debt discount and fully amortized upon conversion of the note into shares of the Common Stock issuable upon conversion of Note B are collectively referred to herein as the “Securities.”

All principal and interest due and owing under Note B is convertible into shares of Common Stock at any time at the election of the holder at a conversion price per share equal to the lower of (i) $0.2495 or (ii) 85% of the lowest daily volume weighted average price of the Common Stock in the fifteen (15) trading days prior to the conversion date (“Conversion Price B”), which Conversion Price B is subject to adjustment for (i) stock splits, stock dividends, combinations, or similar events and (ii) full ratchet anti-dilution protection. Upon certain events of default, the conversion price of Note B will automatically become 70% of the average of the three (3) lowest volume weighted average prices of the Common Stock in the twenty (20) consecutive trading days prior to the conversion date for so long as such event of default remains in effect. All interest payments under the Note are payable, at the Company’s option, in cash or shares of Common Stock.

15
Table of Contents

NOTE 8 – NOTES PAYABLE(Continued)common stock.

 

In addition, at any time that (i)June 2018, the daily volume weighted average priceCompany issued a 7.5% convertible note for an aggregate value of $5,000,000. During June 2018, $1,000,000 plus interest was converted into 438,870 shares of the Common Stock for the prior ten (10) consecutive trading days is $0.70 or more and (ii) the average daily trading valueCompany’s common stock. As of June 30, 2018, $4,000,000 principal, gross of the Common Stock is greater than $2,500,000 forunamortized debt discount of $1,877,741 remains due. There were no fees or expenses deducted from the prior ten (10) consecutive trading days, thennet proceeds received by the Company may demand, upon one (1) day’s notice, thatin the holder convert Note B at Conversion Price B.offerings. The Company paid $150,000 in cash in connection with the notes. The cash fee was recorded as a debt discount.

2017 Master Securities Purchase and Convertible Promissory Notes Agreement

 

The Company may prepayhas a Securities Purchase Agreement with an accredited investor pursuant to which the Company sells to the accredited investor Senior Convertible Promissory Notes. During the year ended December 31, 2017, the Company issued five 12% convertible notes for an aggregate value of $20,000,000 due at various dates through June 2019. Of the $20,000,000 convertible notes issued during 2017, the Company converted $13,100,000 of the convertible notes into shares of the Company’s common stock during the year ended December 31, 2017. As of December 31, 2017, $6,900,000 principal, gross of the unamortized debt discount of $4,790,602 remained due. The convertible notes outstanding as of December 31, 2017 were all converted in January 2018. In January 2018, the Company issued a 12% convertible note for an aggregate value of $5,000,000. Of the $5,000,000 convertible note issued in January, the Company converted all of the convertible note during the six months period ended June 2018. As of June 30, 2018, the related unamortized debt discount was completely amortized. There were no fees or expenses deducted from the net proceeds received by the Company in the offerings. The Company paid $150,000 in cash any portionand issued approximately $196,000 of warrants in connection with the outstanding principal amount of Note Bnotes. The cash fee and any accrued and unpaid interest by, upon ten (10) days’ written notice to the holder, paying an amount equal to (i) 110% of the sum of the then-outstanding principal amount of Note B plus accrued but unpaid interest, if the prepayment date is within 90 days of the issuance date of Note B; (ii) 115% of the sum of the then-outstanding principal amount of Note B plus accrued but unpaid interest, if the prepayment date is between 91 days and 180 days of the issuance date of Note B; or (iii) 125% of the sum of the then-outstanding principal amount of Note B plus accrued but unpaid interest, if the prepayment date is after 180 days of the issuance date of Note B.warrants issued were recorded as a debt discount.

 

NOTE 9 – CONTINGENT CONSIDERATION LIABILITYConversion of Notes Payable and Related Loss on Extinguishment of Debt

 

The Company accounts for “contingent consideration” according to FASB ASC 805, “Business Combinations”. Contingent consideration typically represents the acquirer’s obligation to transfer additional assets or equity interests to the former owners of the acquiree if specified future events occur or conditions are met. FASB ASC 805 requires that contingent consideration be recognized at the acquisition-date fair value as part of the consideration transferred in the transaction.

In the acquisition of Black Oak, the Company valued the contingent consideration based on an analysis using a cash flow model to determine the expected contingent consideration payment, which model determined that the aggregate expected contingent consideration liability was $15,305,463 and the present value of the contingent consideration liability was $12,754,553. Accordingly, the Company recognized at April 1, 2016, the closing date of the Black Oak merger, a $12,754,553 contingent consideration liability associated with the contingent consideration paid pursuant to the Merger Agreement.

On April 1, 2017, the anniversary date of the acquisition and the settlement date of the contingent consideration, the final contingent consideration was approximately $16.5 million. A summary of the changes in the contingent consideration as well as the detail is below:

 

 

Amount

 

 

 

 

 

Contingent Consideration Summary

 

 

 

 

 

 

 

Balance at December 31, 2016

 

$12,085,859

 

Change in Fair Market Valuation of Contingent Consideration

 

 

4,348,761

 

 

 

 

 

 

Balance at March 31, 2017 and April 1, 2017

 

$16,434,620

 

 

 

 

 

 

Contingent Consideration Detail

 

 

 

 

 

 

 

 

 

Performance-Based Cash Contingent Consideration

 

$2,088,000

 

Market-Based Stock Contingent Consideration

 

 

14,346,620

 

 

 

 

 

 

 

 

$16,434,620

 

Changes in the fair market valuation of the contingent consideration are recognized in the consolidated statements of operations. ForDuring the three and six months ended June 30, 2018 and 2017, the Company converted debt and accrued interest into shares of the Company’s common stock, respectively. The table below details the conversion of the notes payable into equity, the loss on fair market valuationextinguishment of contingent consideration was $77,286,debt and $4,426,047, respectively.value of the Company’s common stock issued in conversion of debt for the three and six months ended June 30, 2018 and 2017:

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

Fair market value of common stock issued upon conversion 

 

$12,745,924

 

 

$6,717,694

 

 

$29,926,761

 

 

$11,732,355

 

Principal amount of debt converted 

 

 

(8,500,000)

 

 

(5,005,000)

 

 

(17,900,000)

 

 

(8,564,324)
Accrued interest converted 

 

 

(108,667)

 

 

(145,121)

 

 

(193,279)

 

 

(274,760)
Fair value of derivative at conversion date 

 

 

(6,141,000)

 

 

(2,901,400)

 

 

(15,572,000)

 

 

(5,672,050)
Debt discount value at conversion date 

 

 

5,131,220

 

 

 

2,972,964

 

 

 

11,597,241

 

 

 

5,457,374

 

Loss on extinguishment of debt 

 

$3,127,477

 

 

$1,639,137

 

 

$7,858,723

 

 

$2,678,595

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common Stock Issued Upon Conversion

 

 

4,170,219

 

 

 

2,295,292

 

 

 

7,303,244

 

 

 

4,100,698

 

 
16
 
Table of Contents

NOTE 9 – CONTINGENT CONSIDERATION LIABILITY(Continued)

During April 2017, in final settlement of the contingent consideration, the Company issued approximately $4.7 million in shares of its common stock, or common stock equivalent of approximately 18.1 million shares of its common stock, and made a cash payment of approximately $2.1 million. A summary is as follows:

Contingent Consideration Balance at March 31, 2017

 

$16,434,620

 

 

 

 

 

 

Change in Fair Market Valuation of Contingent Consideration

 

 

77,286

 

Payment of Contingent Consideration in Cash

 

 

(2,088,000)

Settlement of Contingent Consideration

 

 

(4,739,638)

Settlement of Contingent Consideration Recorded Against Additional Paid-In Capital

 

 

(4,692,697)

Gain on Settlement of Contingent Consideration

 

 

(4,991,571)

 

 

 

 

 

Contingent Consideration Balance at June 30, 2017

 

$

 

Pursuant to the terms of the contingent consideration as outlined in the Merger Agreement, the Company was required to release from escrow shares worth approximately $14.4 million. Of those shares, 18.1 million shares, with a value of $4,789,638, were issued in final settlement of the Market-Based Contingent Consideration, and approximately 34.2 million shares were additionally clawed-back. The Market-Based Clawback associated with common stock equivalent of approximately 35.1 million shares were clawed-back pursuant to the appreciation of the quoted price of the Company’s stock underlying the market-based component of the contingent consideration. An additional common stock equivalent of approximately 34.2 million shares, with a value of $9,684,268, were clawed-back pursuant to disputes between the sellers of Black Oak and the Company with respect to certain operational and performance goals that would have impacted the appreciation of the quoted price of the Company’s common stock underlying the market-based component of the contingent consideration and, in effect, increasing the number of clawback shares. For the three and six months ended June 30, 2017, the Company recognized a gain on settlement of contingent consideration of $4,991,571. The balance attributable to related parties was recorded in additional paid in capital. 

See “Note 10 – Fair Value Measurements” for further information.

17
Table of Contents

 

NOTE 109 – FAIR VALUE MEASUREMENTS

 

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

 

The following tables set forth the financial liabilities measured at fair value on a recurring basis by level within the fair value hierarchy as of the dates indicated:

 

 

Fair Value at

June 30,

 

Fair Value Measurement Using

 

 

Fair Value at

June 30,

 

Fair Value Measurement Using 

 

Description

 

2017

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

2018

 

Level 1 

 

Level 2 

 

Level 3 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities – Conversion Feature

 

$3,163,000

 

 

$

 

 

$

 

 

$3,163,000

 

 

$1,891,400

 

$-

 

$-

 

$1,891,400

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$3,163,000

 

 

$

 

 

$

 

 

$3,163,000

 

 

$1,891,400

 

$-

 

$-

 

$1,891,400

 


 

 

Fair Value at December 31,

 

 

Fair Value Measurement Using

 

Description

 

2016

 

 

Level 1

 

Level 2

 

 

Level 3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities – Conversion Feature

 

$6,987,000

 

$

 

$

 

 

$6,987,000

 

Liability – Contingent Consideration

 

$

12,085,859

 

 

 

 

 

 

 

12,085,859

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$19,072,859

 

$

 

$

 

 

$19,072,859

 

No financial assets were measured on a recurring basis as of June 30, 2017 and December 31, 2016.

 

 

 

 

 

 

 

 

Fair Value at December 31, 

 

 

Fair Value Measurement Using 

Description 

 

2017

 

 

Level 1 

 

 

Level 2 

 

 

Level 3 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative Liabilities – Conversion Feature

 

$9,331,400

 

 

$-

 

 

$-

 

 

$9,331,400

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$9,331,400

 

 

$-

 

 

$-

 

 

$9,331,400

 

 

The following table presents a reconciliation of the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3):

Balance at December 31, 2017 

 

$9,331,400

 

 

 

 

 

 

Change in Fair Market Value of Conversion Feature

 

 

(628,000)

Derivative Debt Converted into Equity

 

 

(15,572,000)

Fair Value of Derivative Liability Recorded Upon Issuance of Convertible Debt

 

 

8,760,000

 

 

 

 

 

 

Balance at June 30, 2018

 

$1,891,400

 

17
Table of Contents

Effective as of June 2018, the Company estimates the fair value of any new derivative liabilities using the Monte Carlo Simulation (“MCS”) technique because it provides for the six months ended June 30, 2017:necessary assumptions and inputs. The MCS technique, which is an option-based model, is a generally accepted valuation technique for valuing embedded conversion features in convertible notes, because it is an open-ended valuation model that embodies all significant assumption types, and ranges of assumption inputs that the Company agrees would likely be considered in connection with the arms-length negotiation related to the transference of the instrument by market participants. In addition to the typical assumptions in a closed-end option model, such as volatility and a risk-free rate, MCS incorporates assumptions for interest risk, credit risk and redemption behavior. In addition, MCS breaks down the time to expiration into potentially a large population of time intervals and steps. However, there may be other circumstances or considerations, other than those addressed herein, that relate to both internal and external factors that would be considered by market participants as it relates specifically to the Company and the subject financial instruments. The effects, if any, of these considerations cannot be reasonably measured, quantified or qualified.

 

Balance at December 31, 2016

 

$6,987,000

 

 

 

 

 

 

Change in Fair Market Value of Conversion Feature

 

 

(2,597,950)

Derivative Debt Converted into Equity

 

 

(5,672,050)

Issuance of Debt Instruments with Derivatives

 

 

4,446,000

 

 

 

 

 

 

Balance at June 30, 2017

 

$3,163,000

 

Significant inputs into the Monte Carlo Simulation used to calculate the derivative values are as follows:

 

The following table presents a reconciliation

June 2018

Stock Price

$2.16 - $2.88

Conversion and Exercise Price

$1.92 - $2.29

Annual Dividend Yield

0%

Expected Life (Years)

1.44 - 1.50

Risk-Free Interest Rate

2.41% - 2.47%

Expected Volatility

94.50% - 95.00%

For derivative liabilities issued prior to June 2018, the Company estimates the fair value of the contingent consideration liabilityderivative liabilities using the Black-Scholes-Merton option pricing model using the following assumptions for issuances during the period ended:

Stock Price

$2.16 - $6.90

Conversion and Exercise Price

$1.92 - $6.60

Annual Dividend Yield

0%

Expected Life (Years)

0.66 - 2.42

Risk-Free Interest Rate

1.77% - 2.52%

Expected Volatility

62.36% - 103.43%

Volatility is based on historical volatility of our common stock. Historical volatility was computed using weekly pricing observations for our common stock that correspond to the expected term. This method produces an estimate that is representative of our expectations of future volatility over the expected term of these warrants and conversion features.

18
Table of Contents

No financial assets were measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for the six months endedas of June 30, 2017:2018 and December 31, 2017.

Balance at December 31, 2016

 

$12,085,859

 

 

 

 

 

 

Change in Fair Market Valuation of Contingent Consideration

 

 

4,426,047

 

Payment of Contingent Consideration in Cash

 

 

(2,088,000)

Settlement of Contingent Consideration

 

 

(4,739,638)

Settlement of Contingent Consideration Recorded Against Additional Paid-In Capital

 

 

(4,692,697)

Gain on Settlement of Contingent Consideration

 

 

(4,991,571)

 

 

 

 

 

Balance at June 30, 2017

 

$

 

 

Non-Financial Assets Measured at Fair Value on a Non-Recurring Basis

 

Non-financial assets, such as property, equipment and leasehold improvements, goodwill, and intangible assets, are required to be measured at fair value only when an impairment loss is recognized. The Company did not record an impairment charge related to these assets during the three and six months ended June 30, 2017 and 2016.

18
Table of Contents

 

NOTE 1110INCOME TAXESTAX EXPENSE

 

For the three and six months ended June 30, 20172018 and 2016,2017, the Company had no income tax expense (benefit).

 

As of June 30, 2017 and December 31, 2016, theThe components of deferred income tax assets and deferred income tax liabilities consisted of the following:(liabilities) are as follows:

 

 

June 30,

2017

 

 

December 31,

2016

 

 

June 30,

 

December 31,

 

 

 

 

 

 

 

 

2018

 

2017

 

Deferred Income Tax Assets:

 

 

 

 

 

 

 

 

 

 

Warrants Expense

 

$4,832,000

 

$4,186,000

 

Derivatives Expense

 

6,443,000

 

4,067,000

 

Net Operating Losses

 

19,105,000

 

15,242,000

 

 

$10,426,088

 

$8,023,000

 

 

 

 

 

 

 

 

 

 

 

 

10,426,088

 

8,023,000

 

Deferred Income Tax Liabilities:

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

(1,818,000)

 

 

(1,334,000)

 

 

(926,286)

 

 

(850,000)

 

 

 

 

 

 

 

 

 

 

Total

 

28,562,000

 

22,161,000

 

 

9,499,802

 

7,173,000

 

Valuation Allowance

 

 

(28,562,000)

 

 

(22,161,000)

 

 

(9,499,802)

 

 

(7,173,000)

 

 

 

 

 

 

 

 

 

 

Net Deferred Tax Liabilities

 

$

 

 

$

 

Net Deferred Tax

 

$-

 

$-

 

In December 2017 the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code that affects revaluation of deferred tax assets and liabilities to reflect the federal tax rate reduction from 35.0% to 21.0%.

 

For the three and six months ended June 30, 2018 and 2017, and 2016, certain of the Company’sCompany had subsidiaries that produced and sold cannabis or cannabis pure concentrates, subjecting the Company to the limits of IRCInternal Revenue Code (“IRC”) Section 280E. Pursuant to IRC Section 280E, the Company is allowed only to deduct expenses directly related to sales of product. The State of California does not conform to IRC Section 280E and, accordingly the Company is allowed to deduct all operating expenses on its California income tax returns. As the Company files consolidated federal income tax returns, the taxable income generated from its subsidiaries subject to IRC Section 280E has been offset by losses generated by operations not subject to IRC Section 280E. During 2017, Company amended income tax returns of our subsidiary Black Oak Gallery, a California Corporation (“Black Oak”) for the periods prior to acquisition, which resulted in a net tax refund in 2017.

 

Permanent tax differences include ordinary and necessary business expenses deemed by the Company as a non-allowable deductiondeductions under IRC Section 280E,280E; non-deductible expenses for interest, derivatives and tax deductionswarrant expense related to equity compensation that are less than the compensation recognized for financial reporting.debt financings and non-deductible losses related to various acquisitions.

19
Table of Contents

 

As of June 30, 20172018 and December 31, 2016,2017, the Company had net operating loss carryforwards of $42,623,000approximately $33,822,483 and $34,940,000,$26,333,000, respectively, which, if unused, will expire beginning in the year 2034. These tax attributes are subject to an annual limitation from equity shifts, which constitute a change of ownership as defined under Internal Revenue Code (“IRC”)IRC Section 382, which will limit their utilization. The Company has yet to assessassessed the effect of these limitations but expectsand does not believe these losses to be substantially limited. Accordingly, the Company has placed a reserve against any assets associated with these losses.

The Company files incomealso has deferred tax returns inliabilities from the U.S. federal jurisdiction and various state and local jurisdictions. All tax years from 2012 to 2015 are subject to examination.excess carrying amounts of the basis of depreciable assets for financial reporting purposes.

 

Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. A significant piece of objective negative evidence evaluated was the cumulative losses incurred in 2017 and through the six months period ended June 30, 2017.2018. Such objective evidence limits the ability to consider other subjective evidence, such as our projections for future growth. On the basis of this evaluation, as of June 30, 2017,2018, a valuation allowance of $9,499,802 has been recorded against all net deferred tax assets as these assets are more likely than not to be unrealized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence such as our projections for growth.

 
19
Table of Contents

The Company files income tax returns in the U.S. federal jurisdiction and various state and local jurisdictions. All tax years from 2014 to 2017 are subject to examination.

 

NOTE 1211 – EQUITY

Preferred Stock

Series A Preferred Stock is convertible on a one-for-one basis into common stock and has all of the voting rights of the Company’s common stock.

Each share of Series B Preferred Stock: (i) is entitled to 100 votes for each share of common stock into which a share of Series B Preferred Stock is convertible and (ii) is convertible, at the option of the holder, on a 1-for-5.384325537 basis, into shares of the Company’s common stock.

See “Note 16 – Subsequent Events” for additional disclosure regarding changes to the Company’s Series B Preferred Stock subsequent to June 30, 2017.

During the six months ended June 30, 2017, the Company issued 600,000 shares of Series B Preferred Stock for compensation in the amount of $1,035,406.

During the six months ended June 30, 2017, the Company cancelled 4,279,841 shares of Series B Preferred Stock that had been previously issued and held in escrow in connection with the contingent consideration related to the Black Oak acquisition. See “Note 9 – Contingent Consideration Liability” for further information.

 

Common Stock

 

During the six months ended June 30, 2017,2018, senior secured convertible promissory notes and accrued interest in the amount of $8,839,084$29,926,761 were converted into 50,710,4737,303,244 shares of common stock.

 

During the six months ended June 30, 2017,2018, the Company issued 17,674,027sold 1,314,147 shares of common stock for cash in the net amount of $3,750,000$3,650,000 pursuant to an equity financing facility with an accredited investor.

 

During the six months ended June 30, 2017,2018, the Company issued 1,215,909cancelled 24,510 shares of common stock for director fees in the amount of $221,973,valued at $117,831, issued 2,859,00544,282 shares of common stock for services performed in the amount of $591,359$123,727 and issued 1,635,780173,394 shares of common stock for compensation in the amount of $320,732.$552,992.

 

During the six months ended June 30, 2017,2018, the Company cancelled 9,291,744issued 224,925 shares of common stock that had been previously issuedfor cashless and held in escrow in connection withcash exercises of warrants. The cash received from the contingent consideration related to the Black Oak acquisition. See “Note 9 – Contingent Consideration Liability” for further information.cash exercise of warrants was $76,000.

 

During the six months ended June 30, 2016, senior secured convertible promissory notes and accrued interest2018, the Company purchased an asset worth $300,000. $100,000 was paid in cash during March 2018, the amount of $961,740 were converted into 13,906,149remaining $200,000 was paid by issuing 53,332 shares of the Company’s common stock.

 

During the six months ended June 30, 2016,2018, as part of the stock split in March 2018, the Company sold 25,715,674issued 46,687 shares of common stock forto round up fractional shares to all shareholders of the net amountCompany.

During the six months ended June 30, 2018, as part of $3,208,134 pursuantthe acquisition of Tech Center Drive in September 2017, the Company issued shares held in escrow which were to an equity financing facility with an accredited investor.be paid six months after the acquisition date subject to any amounts to be withheld related to working capital type adjustments. As a result of the working capital adjustments, in March 2018, approximately $351,000 on the six-month anniversary date, the Company withheld and cancelled 101,083 shares.

 
 
20
 
Table of Contents

 

NOTE 12 – EQUITY (Continued)STOCK-BASED COMPENSATION

 

Stock-Based Compensation Expense2016 Equity Incentive Plan

 

A summaryIn the first quarter of stock-based compensation2016, the Company adopted the 2016 Equity Incentive Plan. The following table contains information about the 2016 Equity Incentive Plan as of June 30, 2018:

 

 

Awards Reserved for Issuance

 

 

Awards Issued

 

 

Awards Available for Grant

 

2016 Equity Incentive Plan

 

 

30,000,000

 

 

 

2,044,399

 

 

 

27,955,601

 

 

Stock Options

The following table summarizes the Company’s stock option activity and related information for the three months ended June 30, 2017 and 2016 is as follows:

 

 

For the Three Months Ended

 

 

 

June 30, 2017

 

 

June 30, 2016

 

Type of Award

 

Number of Shares or Options Granted

 

 

Stock-Based Compensation Expense

 

 

Number of Shares or Options Granted

 

 

Stock-Based Compensation Expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Options

 

 

8,250,000

 

 

$157,430

 

 

 

 

 

$47,589

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Grants:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employees (Common Stock)

 

 

1,535,780

 

 

 

294,632

 

 

 

 

 

 

 

Employees (Series B Preferred Stock)

 

 

 

 

 

 

 

 

 

 

 

 

Directors (Common Stock)

 

 

1,090,909

 

 

 

184,473

 

 

 

 

 

 

 

Non–Employee Consultants (Common Stock)

 

 

2,391,358

 

 

 

446,348

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Stock-Based Compensation

 

 

13,268,047

 

 

$1,082,883

 

 

 

 

 

$47,589

 

A summary of stock-based compensation for the six months ended June 30, 2017 and 2016 is as follows:2018:

 

 

 

For the Six Months Ended

 

 

 

June 30, 2017

 

 

June 30, 2016

 

Type of Award

 

Number of
Shares or
Options
Granted

 

 

Stock-Based Compensation Expense

 

 

Number of
Shares or
Options
Granted

 

 

Stock-Based Compensation Expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Options

 

 

8,250,000

 

 

$205,019

 

 

 

6,700,000

 

 

$95,178

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Grants:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employees (Common Stock)

 

 

1,635,780

 

 

 

320,732

 

 

 

 

 

 

 

Employees (Series B Preferred Stock)

 

 

600,000

 

 

 

1,035,406

 

 

 

 

 

 

 

Directors (Common Stock)

 

 

1,215,909

 

 

 

221,973

 

 

 

350,000

 

 

 

60,550

 

Non–Employee Consultants (Common Stock)

 

 

2,859,005

 

 

 

591,359

 

 

 

70,000

 

 

 

20,727

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Stock–Based Compensation

 

 

14,560,694

 

 

$2,374,489

 

 

 

7,120,000

 

 

$176,455

 

NOTE 13 – COMMITMENTS

Operating Lease Commitments

The Company leases certain business facilities under operating lease agreements that specify minimum rentals. Many of these have renewal provisions. The Company’s net rent expense for the three months ended June 30, 2017 and 2016 was $312,254 and $298,092, respectively, and for the six months ended June 30, 2017 and 2016 was $627,067 and $431,959, respectively.

 

 

Number of Shares 

 

 

Weighted-Average Exercise Price Per Share 

 

 

Weighted-Average Remaining Contractual Life 

 

Aggregate Intrinsic Value of In-the-Money Options 

 

Options Outstanding as of Janury 1, 2018

 

 

1,177,732

 

 

$2.17

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Granted

 

 

800,000

 

 

$4.41

 

 

 

 

 

 

Options Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

Options Forfeited

 

 

-

 

 

 

-

 

 

 

 

 

 

Options Expired

 

 

-

 

 

 

-

 

 

 

 

 

 

Options Outstanding as of March 31, 2018

 

 

1,977,732

 

 

$3.08

 

 

 9.1 Years 

 

$522,600

 

Options Exercisable as of Mach 31, 2018

 

 

659,774

 

 

$2.20

 

 

 8.5 Years 

 

$391,950

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Options Granted

 

 

66,667

 

 

$3.75

 

 

 

 

 

 

 

Options Exercised

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Options Forfeited

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Options Expired

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Options Outstanding as of June 30, 2018

 

 

2,044,399

 

 

$3.10

 

 

 8.89 Years 

 

$361,800

 

Options Exercisable as of June 30, 2018

 

 

828,941

 

 

$2.38

 

 

 8.42 Years 

 

$301,500

 

 

 
21
 
Table of Contents

  

The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price of $2.16 on June 30, 2018 and the exercise price of options, multiplied by the number of options. As of June 30, 2018, there was $3,984,837 total unrecognized stock-based compensation. Such costs are expected to be recognized over a weighted-average period of approximately 1.74 years.

The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The following assumptions were used to calculate stock-based compensation for issuances during the six months ended June 30, 2018.

June 2018

Expected Term (years)

6.5 Years

Volatility

126.93-128.0%

Risk-Free Interest Rate

2.5-2.8%

Dividend Yield

0%

The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Hence, the Company uses the “simplified method” described in Staff Accounting Bulletin 107 to estimate the expected term of share option grants.

The expected stock price volatility assumption was determined by examining the historical volatilities for the Company’s common stock. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company’s common stock becomes available.

The risk-free interest rate assumption is based on the U.S. treasury instruments whose term was consistent with the expected term of the Company’s stock options.

The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Accordingly, the Company has assumed no dividend yield for purposes of estimating the fair value of the Company stock-based compensation.

The Company estimates the forfeiture rate at the time of grant and revisions, if necessary, were estimated based on management’s expectation through industry knowledge and historical data.

Stock-Based Compensation Expense

The following table sets forth the total stock-based compensation expense resulting from stock options and restricted grants of common stock to employees, directors and non-employee consultants in the consolidated statement of operations which are included in selling, general and administrative expenses:

 

 

For the Three Months Ended

 

 

 

June 30, 2018

 

 

June 30, 2017

 

Type of Award 

 

Number of Shares or Options Granted

 

 

Stock-Based Compensation Expense 

 

 

Number of Shares or Options Granted

 

 

Stock-Based Compensation Expense 

 

Stock Options

 

 

66,667

 

 

$480,500

 

 

 

550,000

 

 

$157,430

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Grants:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employees (Common Stock)

 

 

91,888

 

 

 

264,542

 

 

 

102,385

 

 

 

294,632

 

Employees (Series B Preferred Stock)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Directors (Common Stock)

 

 

-

 

 

 

-

 

 

 

72,728

 

 

 

184,473

 

Non–Employee Consultants (Common Stock)

 

 

37,872

 

 

 

107,037

 

 

 

159,424

 

 

 

446,348

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Stock–Based Compensation Expense

 

 

 

 

 

$852,079

 

 

 

 

 

 

$1,082,883

 

22
Table of Contents

 

 

For the Six Months Ended

 

 

 

June 30, 2018

 

 

June 30, 2017

 

Type of Award 

 

Number of Shares or Options Granted

 

 

Stock-Based Compensation Expense 

 

 

Number of Shares or Options Granted

 

 

Stock-Based Compensation Expense 

 

Stock Options

 

 

866,667

 

 

$954,698

 

 

 

550,000

 

 

$205,019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock Grants:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employees (Common Stock)

 

 

173,394

 

 

 

552,992

 

 

 

109,052

 

 

 

320,732

 

Employees (Series B Preferred Stock)

 

 

-

 

 

 

-

 

 

 

40,000

 

 

 

1,035,406

 

Directors (Common Stock)

 

 

-

 

 

 

-

 

 

 

81,061

 

 

 

221,973

 

Non–Employee Consultants (Common Stock)

 

 

44,282

 

 

 

123,727

 

 

 

190,600

 

 

 

591,359

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Stock–Based Compensation Expense

 

 

 

 

 

$1,631,417

 

 

 

 

 

 

$2,374,489

 

NOTE 13 – COMMITMENTS (Continued)WARRANTS

 

Production Operating Agreement

On May 23, 2017,The Company has the Company entered into a one-year operating agreement with Panther Gap Farms pursuant to which Panther Gap Farms will grow up to approximately one metric tonfollowing shares of common stock reserved for exercise of the Company’s IVXX cannabis annually. The operating agreement is renewable for up to three additional terms of one year each. The agreement also requires the Company to issue common stock, with a value of $1,150,000, upon execution of the agreement, which the Company had not issuedwarrants outstanding as of June 30, 2017. In addition2018:

 

 

Shares

 

 

Weighted-Average Exercise Price

 

Warrants Outstanding as of January 1, 2018

 

 

1,191,367

 

 

$2.85

 

Warrants Exercised

 

 

(283,697)

 

$2.17

 

Warrants Granted

 

 

114,636

 

 

$4.05

 

Warrants Expired

 

 

-

 

 

$-

 

Warrants Outstanding as of March 31, 2018

 

 

1,022,306

 

 

$3.80

 

 

 

 

 

 

 

 

 

 

Warrants Exercised

 

 

(27,800)

 

$0.90

 

Warrants Granted

 

 

51,026

 

 

$2.94

 

Warrants Expired

 

 

(26,710)

 

$3.09

 

Warrants Outstanding as of June 30, 2018

 

 

1,018,822

 

 

$3.25

 

23
Table of Contents

The following weighted-average assumptions were used to calculate the common stock,fair value of warrants issued during the Company is required to issue common stockperiod ended June 30, 2018 and 2017 using the Black Scholes option pricing model:

 

 

 

June 30,

 

 

 

June 30,

 

 

 

2018

 

 

 

2017

 

Stock Price on Date of Grant

 

$3.45

 

 

$4.94

 

Exercise Price

 

$3.71

 

 

$2.64

 

Volatility

 

 

118.90%

 

 

133.54%
Term

 

 

5.00Yrs

 

 

5.00Yrs
Risk-Free Interest Rate

 

 

2.50%

 

 

1.53%
Expected Dividend Rate

 

 

0%

 

 

0%

There were no warrants recognized as an expense for the profit sharethree and six months period ended June 30, 2018. There were no warrants recognized as an expense for the three months period June 30, 2017. Warrant expense of $211,534 was recognized for the cannabis ultimately sold bysix months period June 30, 2017. Warrants of $475,916 for the Company upon execution of the agreement. The shares to be received by Panther Gap Farms under the profit share agreement are dependent on the ultimate profit recognized by the Company when the cannabis product is sold. As ofsix months ended June 30, 2018 were recorded for warrants issued in connection with debt and recorded as a debt discount.

Warrant expense was $104,499 and $211,534 for three and six months ended June 30, 2017, respectively. For the Company has notthree and six months period ended June 30, 2017, there were no warrants issued the required shares.in connection with debt and recorded as a debt discount.

 

NOTE 14 – COMMITMENTS AND CONTINGENCIES

California Operating Licenses

Effective January 1, 2018 the State of California allowed for adult use cannabis sales. California’s cannabis licensing system is being implemented in two phases. First, beginning on January 1, 2018, the State began issuing temporary licenses. Temporary licenses were initially issued for 90 days, but have since been extended twice by the state. Our current temporary licenses expire on October 28, 2018. The extensions were initially provided because in May the Company had submitted all the necessary documentation for an annual license to be issued. Prior to the state completing its review of any annual licenses, the licensing authority Bureau Cannabis Control (“BCC”) determined that they would eliminate the need to have multiple licenses issued to each entity for both medical and adult use. What this meant was that the State would allow for an entity to apply for a consolidated license which allowed the entities to sell both medical and recreational cannabis. The Company has since applied for single category licenses that allow our vertically integrated activities to conduct sales in both the medical and Panther Gap Farmsadult use categories. The decision by the regulating authority meant that the cost of the annual licenses would also entered intobe reduced as prior to this change we would have had to apply for two licenses one in each category and they each bore a lease agreement pursuantmulti-thousand dollar expense. The Company’s prior licenses obtained from the local jurisdictions in which it operated in have been continued by such jurisdictions and are necessary to obtain state licensing. The Company has received a temporary license for each local jurisdiction which it had active operations. The temporary permits may be extended for an additional period of time. The Company submitted its applications for the annual permits in April 2018. Although the Company leasesbelieves it will receive the propertynecessary licenses from the State to conduct its business in a timely fashion, there is no guarantee the Company will be able to do so and any failure to do so may have a negative effect on whichits business and results of operations.

24
Table of Contents

Although the possession, cultivation and distribution of cannabis for medical and adult use is permitted in California and Nevada, cannabis is grown. The lease agreement requires monthly paymentsa Schedule-I controlled substance and its use remains a violation of $30,000 for eight monthsfederal law. Since federal law criminalizing the use of cannabis preempts state laws that legalize its use, strict enforcement of federal law regarding cannabis would likely result in our inability to proceed with our business plan, especially in respect of our cannabis cultivation, production and dispensaries. In addition, our assets, including real property, cash, equipment and other goods, could be subject to asset forfeiture because cannabis is also renewable for up to three additional terms of one year each.still federally illegal.

 

NOTE 1415 – SEGMENT INFORMATION

 

The Company’s operating and reportable segments are currently organized around the following products that it offers as part of its core business strategy:

 

·

·

Herbs and Produce Products – Includes herbs and leafy greens that are grown using classic Dutch hydroponic farming methods.

·

·

Cannabis Dispensary, Cultivation and Production – Includes cannabis-focused retail, cultivation and production.

 

These two reportable segments, which are described in greater detail below, had previously been reported on a combined basis as they had been operated and evaluated as one operating segment. The Company experienced significant growth over the last few years in most of our product areas. As the Company has grown organically, and as the Company previously added to its capabilities through acquisitions, its products have increased in scale and become more strategically important and distinctly organized and managed under these two groupings. In addition, Derek Peterson, the Company’s Chief Operating Decision Maker (“CODM”), reviews results, manages and allocates resources between these two strategic business groupings, and budgets using these business segments. The Company’s CODM reviews revenues including intersegment revenues, gross profit and operating income (loss) before income taxes when evaluating segment performance and allocating resources to each segment. Accordingly, intersegment revenue is included in the segment revenues presented in the tables below and is eliminated from revenues and cost of goods sold in the “Eliminations and Other” column. The “Eliminations and Other” column also includes various income and expense items that the Company does not allocate to its operating segments. These income and expense amounts include the results of the Company’s hydroponic equipment, which are not material, interest income, interest expense, corporate overhead, and corporate-wide expense items such as legal and professional fees as well as expense items for which we have not identified a reasonable basis for allocation. The accounting policies of the reportable segments are the same as those described in “Note 2 - Summary of Significant Accounting Policies” of the Notes to Unaudited Consolidated Financial Statements.

Herbs and Produce Products

Either independently or in conjunction with third parties, we are a retail seller of locally grown hydroponic herbs, produce, and floral products, which are distributed through major grocery stores throughout the East and Midwest regions of the U.S.

22
Table of Contents

NOTE 14 – SEGMENT INFORMATION(Continued)

Cannabis Dispensary, Cultivation and Production

Either independently or in conjunction with third parties, we operate medical marijuana retail dispensaries, medical marijuana cultivation and production facilities in California and Nevada. We own real property in Nevada on which we plan to build a medical marijuana dispensary. All of our retail dispensaries in California and Nevada offer a broad selection of medical cannabis products including flowers, concentrates and edibles. We also produce and sell a line of medical cannabis flowers, as well as a line of medical cannabis-extracted products, which include concentrates, cartridges, vape pens and wax products.

Summarized financial information concerning the Company’s reportable segments is shown in the following tables. Total assetsasset amounts at June 30, 20172018 and 20162017 exclude intercompany receivable balances eliminated in consolidation.

 

 

For the Three Months Ended June 30, 2017

 

 

Herbs and Produce Products

 

 

Cannabis Dispensary, Cultivation and Production

 

 

Eliminations and Other

 

 

Total

 

 

For the Three Months Ended June 30, 2018
(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Herbs and Produce Products 

 

Cannabis Dispensary, Cultivation and Production 

 

Eliminations and Other 

 

Total 

 

Total Revenues

 

$1,777,067

 

$6,049,319

 

$16,487

 

$7,842,873

 

 

$1,502,789

 

$7,203,971

 

$11,417

 

$8,718,177

 

Cost of Goods Sold

 

 

1,325,729

 

 

 

5,010,771

 

 

 

 

 

 

6,336,500

 

 

 

958,694

 

 

5,551,060

 

 

-

 

 

6,509,754

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

451,338

 

1,038,548

 

16,487

 

1,506,373

 

 

544,095

 

1,652,911

 

11,417

 

2,208,423

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

855,999

 

 

 

2,210,475

 

 

 

2,962,813

 

 

 

6,029,287

 

 

 

994,906

 

 

2,823,524

 

 

4,183,940

 

 

8,002,370

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(404,661)

 

 

(1,171,927)

 

 

(2,946,326)

 

 

(4,522,914)

 

 

(450,811)

 

 

(1,170,613)

 

 

(4,172,523)

 

 

(5,793,947)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

 

(515,654)

 

(515,654)

 

-

 

-

 

(417,363)

 

(417,363)

Loss on Extinguishment of Debt

 

 

 

(1,639,137)

 

(1,639,137)

 

-

 

-

 

(3,127,477)

 

(3,127,477)

Gain on Fair Market Valuation of Derivatives

 

 

 

987,200

 

987,200

 

Loss on Fair Market Valuation of Derivatives

 

-

 

-

 

(1,653,000)

 

(1,653,000)

Interest Expense

 

 

 

(130,510)

 

(130,510)

 

 

-

 

 

-

 

 

(331,379)

 

 

(331,379)

Loss on Fair Market Valuation of Contingent Consideration

(77,286

)

(77,286

)

Gain on Settlement of Contingent Consideration

4,991,571

4,991,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

 

 

 

4,914,285

 

 

(1,298,101)

 

 

3,616,184

 

 

 

-

 

 

-

 

 

(5,529,219)

 

 

(5,529,219)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

$(404,661)

 

$3,742,358

 

 

$(4,244,427)

 

$(906,730)
Net Loss

 

$(450,811)

 

$(1,170,613)

 

$(9,701,742)

 

$(11,323,166)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2017

 

$7,104,469

 

$60,224,138

 

$9,550,062

 

$76,878,669

 

Total Assets at June 30, 2018

 

$6,320,906

 

$71,591,669

 

$31,878,438

 

$109,791,013

 

 

 

For the Three Months Ended June 30, 2016

 

 

 

Herbs and Produce Products

 

 

Cannabis Dispensary, Cultivation and Production

 

 

Eliminations and Other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$5,873,418

 

 

$3,768,977

 

 

$57,514

 

 

$9,699,909

 

Cost of Goods Sold

 

 

5,517,052

 

 

 

2,596,035

 

 

 

39,848

 

 

 

8,152,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

356,366

 

 

 

1,172,942

 

 

 

17,666

 

 

 

1,546,974

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

756,405

 

 

 

1,649,452

 

 

 

2,958,494

 

 

 

5,364,351

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(400,039)

 

 

(476,510)

 

 

(2,940,828)

 

 

(3,817,377)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

 

 

 

 

 

 

(218,126)

 

 

(218,126)

Loss from Derivatives Issued with Debt Greater than Debt Carrying Value

 

 

 

 

 

 

 

 

(488,000)

 

 

(488,000)

Loss on Fair Market Valuation of Derivatives

 

 

 

 

 

 

 

 

(206,000)

 

 

(206,000)

Interest Income (Expense)

 

 

 

 

 

250

 

 

 

(60,815)

 

 

(60,565)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

 

 

 

250

 

 

 

(972,941)

 

 

(972,691)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

$(400,039)

 

$(476,260)

 

$(3,913,769)

 

$(4,790,068)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2016

 

$6,834,863

 

 

$57,142,755

 

 

$2,784,814

 

 

$66,762,432

 

  
 
2325
 
Table of Contents

 

NOTE 14 – SEGMENT INFORMATION(Continued)

 

 

For the Three Months Ended June 30, 2017
(Unaudited)

 

 

 

Herbs and Produce Products 

 

 

Cannabis Dispensary, Cultivation and Production 

 

 

Eliminations and Other 

 

 

Total 

 

Total Revenues

 

$1,777,067

 

 

$6,049,319

 

 

$16,487

 

 

$7,842,873

 

Cost of Goods Sold

 

 

1,325,729

 

 

 

5,010,771

 

 

 

-

 

 

 

6,336,500

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

451,338

 

 

 

1,038,548

 

 

 

16,487

 

 

 

1,506,373

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

855,999

 

 

 

2,210,475

 

 

 

2,962,813

 

 

 

6,029,287

 

 

 

 

 

 

 

 

 

 

 

.

 

 

 

 

 

Loss from Operations

 

 

(404,661)

 

 

(1,171,927)

 

 

(2,946,326)

 

 

(4,522,914)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

-

 

 

 

-

 

 

 

(515,654)

 

 

(515,654)

Loss on Extinguishment of Debt

 

 

-

 

 

 

-

 

 

 

(1,639,137)

 

 

(1,639,137)

Gain on Fair Market Valuation of Derivatives

 

 

-

 

 

 

-

 

 

 

987,200

 

 

 

987,200

 

Interest Expense

 

 

-

 

 

 

-

 

 

 

(130,510)

 

 

(130,510)

Loss on Fair Market Valuation of Contingent Consideration

 

 

-

 

 

 

(77,286)

 

 

-

 

 

 

(77,286)

Gain on Settlement of Contingent Consideration

 

 

-

 

 

 

4,991,571

 

 

 

-

 

 

 

4,991,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

-

 

 

 

4,914,285

 

 

 

(1,298,101)

 

 

3,616,184

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Income (Loss)

 

$(404,661)

 

$3,742,358

 

 

$(4,244,427)

 

$(906,730)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2017

 

$7,104,469

 

 

$60,224,138

 

 

$9,550,062

 

 

$76,878,669

 

 

 

 

For the Six Months Ended June 30, 2017

 

 

 

Herbs and Produce Products

 

 

Cannabis Dispensary, Cultivation and Production

 

 

Eliminations and Other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$2,694,210

 

 

$11,936,357

 

 

$36,762

 

 

$14,667,329

 

Cost of Goods Sold

 

 

2,295,544

 

 

 

10,506,349

 

 

 

 

 

 

12,801,893

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

398,666

 

 

 

1,430,008

 

 

 

36,762

 

 

 

1,865,436

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

1,515,062

 

 

 

4,837,480

 

 

 

6,063,045

 

 

 

12,415,587

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(1,116,396)

 

 

(3,407,472)

 

 

(6,026,283)

 

 

(10,550,151)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

 

 

 

 

 

 

(1,126,270)

 

 

(1,126,270)

Loss on Extinguishment of Debt

 

 

 

 

 

 

 

 

(2,678,595)

 

 

(2,678,595)

Gain on Fair Market Valuation of Derivatives

 

 

 

 

 

 

 

 

2,597,950

 

 

 

2,597,950

 

Interest Expense

 

 

 

 

 

 

 

 

(288,343)

 

 

(288,343)

Loss on Fair Market Valuation of Contingent Consideration

(4,426,047

)

(4,426,047

)

Gain on Settlement of Contingent Consideration

4,991,571

4,991,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

 

 

 

565,524

 

 

 

(1,495,258)

 

 

(929,734

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

$(1,116,396)

 

$(2,841,948

)

 

$(7,521,541)

 

$(11,479,885)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2017

 

$7,104,469

 

 

$60,224,138

 

 

$9,550,062

 

 

$76,878,669

 

 

 

For the Six Months Ended June 30, 2016

 

 

 

Herbs and Produce Products

 

 

Cannabis Dispensary, Cultivation and Production

 

 

Eliminations and Other

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenues

 

$7,274,861

 

 

$3,899,180

 

 

$74,035

 

 

$11,248,076

 

Cost of Goods Sold

 

 

6,837,431

 

 

 

2,809,296

 

 

 

39,848

 

 

 

9,686,575

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

437,430

 

 

 

1,089,884

 

 

 

34,187

 

 

 

1,561,501

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

1,155,610

 

 

 

1,851,588

 

 

 

4,284,054

 

 

 

7,291,252

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(718,180)

 

 

(761,704)

 

 

(4,249,867)

 

 

(5,729,751)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

 

 

 

 

 

 

(312,532)

 

 

(312,532)

Loss on Extinguishment of Debt

 

 

 

 

 

 

 

 

(920,797)

 

 

(920,797)

Loss from Derivatives Issued with Debt Greater than Debt Carrying Value

 

 

 

 

 

 

 

 

(488,000)

 

 

(488,000)

Loss on Fair Market Valuation of Derivatives

 

 

 

 

 

 

 

 

(1,366,700)

 

 

(1,366,700)

Interest Income (Expense)

 

 

 

 

 

250

 

 

 

(116,810)

 

 

(116,560)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

 

 

 

250

 

 

 

(3,204,839)

 

 

(3,204,589)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss Before Provision for Income Taxes

 

$(718,180)

 

$(761,454)

 

$(7,454,706)

 

$(8,934,340)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2016

 

$6,834,863

 

 

$57,142,755

 

 

$2,784,814

 

 

$66,762,432

 

 
2426
 
Table of Contents

 

 

For the Six Months Ended June 30, 2018

(Unaudited)

 

 

 

Herbs and Produce Products 

 

 

Cannabis Dispensary, Cultivation and Production 

 

 

Eliminations and Other 

 

 

Total 

 

Total Revenues

 

$2,786,690

 

 

$14,518,525

 

 

$28,328

 

 

$17,333,543

 

Cost of Goods Sold

 

 

2,221,811

 

 

 

11,255,869

 

 

 

-

 

 

 

13,477,680

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

564,879

 

 

 

3,262,656

 

 

 

28,328

 

 

 

3,855,863

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

1,937,273

 

 

 

6,827,231

 

 

 

7,660,414

 

 

 

16,424,918

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(1,372,394)

 

 

(3,564,575)

 

 

(7,632,086)

 

 

(12,569,055)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

-

 

 

 

-

 

 

 

(885,680)

 

 

(885,680)

Loss on Extinguishment of Debt

 

 

-

 

 

 

-

 

 

 

(7,858,723)

 

 

(7,858,723)

Gain on Fair Market Valuation of Derivatives

 

 

-

 

 

 

-

 

 

 

628,000

 

 

 

628,000

 

Interest Expense

 

 

-

 

 

 

(397)

 

 

(590,603)

 

 

(591,000)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

-

 

 

 

(397)

 

 

(8,707,006)

 

 

(8,707,403)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$(1,372,394)

 

$(3,564,972)

 

$(16,339,092)

 

$(21,276,458)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2018

 

$6,320,906

 

 

$71,591,669

 

 

$31,878,438

 

 

$109,791,013

 

27
Table of Contents

 

 

For the Six Months Ended June 30, 2017

(Unaudited)

 

 

 

Herbs and Produce Products 

 

 

Cannabis Dispensary, Cultivation and Production 

 

 

Eliminations and Other 

 

 

Total 

 

Total Revenues

 

$2,694,210

 

 

$11,936,357

 

 

$36,762

 

 

$14,667,329

 

Cost of Goods Sold

 

 

2,295,544

 

 

 

10,506,349

 

 

 

-

 

 

 

12,801,893

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit

 

 

398,666

 

 

 

1,430,008

 

 

 

36,762

 

 

 

1,865,436

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, General and Administrative Expenses

 

 

1,515,062

 

 

 

4,837,480

 

 

 

6,063,045

 

 

 

12,415,587

 

 

 

 

 

 

 

 

 

 

 

.

 

 

 

 

 

Loss from Operations

 

 

(1,116,396)

 

 

(3,407,472)

 

 

(6,026,283)

 

 

(10,550,151)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of Debt Discount

 

 

-

 

 

 

-

 

 

 

(1,126,270)

 

 

(1,126,270)

Loss on Extinguishment of Debt

 

 

-

 

 

 

-

 

 

 

(2,678,595)

 

 

(2,678,595)

Gain on Fair Market Valuation of Derivatives

 

 

-

 

 

 

-

 

 

 

2,597,950

 

 

 

2,597,950

 

Interest Expense

 

 

-

 

 

 

-

 

 

 

(288,343)

 

 

(288,343)

Loss on Fair Market Valuation of Contingent Consideration

 

 

-

 

 

 

(4,426,047)

 

 

-

 

 

 

(4,426,047)

Gain on Settlement of Contingent Consideration

 

 

-

 

 

 

4,991,571

 

 

 

-

 

 

 

4,991,571

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Other Income (Expense)

 

 

-

 

 

 

565,524

 

 

 

(1,495,258)

 

 

(929,734)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$(1,116,396)

 

$(2,841,948)

 

$(7,521,541)

 

$(11,479,885)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Assets at June 30, 2017

 

$7,104,469

 

 

$60,224,138

 

 

$9,550,062

 

 

$76,878,669

 

 

NOTE 1516 – LITIGATION AND CLAIMS

 

The Company is the subject of lawsuits and claims arising in the ordinary course of business from time to time. The Company reviews any such legal proceedings and claims on an ongoing basis and follows appropriate accounting guidance when making accrual and disclosure decisions. The Company establishes accruals for those contingencies where the incurrence of a loss is probable and can be reasonably estimated, and it discloses the amount accrued and the amount of a reasonably possible loss in excess of the amount accrued if such disclosure is necessary for the Company’s financial statements to not be misleading. To estimate whether a loss contingency should be accrued by a charge to income, the Company evaluates, among other factors, the degree of probability of an unfavorable outcome and the ability to make a reasonable estimate of the amount of the loss. The Company does not record liabilities when the likelihood that the liability has been incurred is probable, but the amount cannot be reasonably estimated. Based upon present information, the Company determined that there were no matters that required an accrual as of June 30, 2017,2018 nor were there any asserted or unasserted material claims for which material losses are reasonably possible.

28
Table of Contents

On April 11, 2018, the Company filed a lawsuit in the United States District Court, Central District of California against Kenneth Vande Vrede, Michael Vande Vrede, Steven Vande Vrede, Daniel Vande Vrede, Greda Vande Vrede, Beverly Willekes, Brian Vande Vrede, Gro-Rite, Inc. (“Gro-Rite”) and Naturally Beautiful Plant Products, LLC (“Naturally Beautiful”) alleging breach of contract, breach of fiduciary duties, conversion, fraud, breach of covenant of good faith and fair dealing, misappropriation of trade secrets, and conspiracy related to, among other things, the Share Exchange Agreement, dated as of April 24, 2013 among the Company, the Company’s wholly-owned subsidiary, Edible Garden Corp. (“Edible Garden”), and the individual defendants (the “Share Exchange Agreement”). The Company is seeking monetary damages, including attorneys’ fees and expenses, return of shares of the Company’s common stock issued to the individual defendants under the Share Exchange Agreement, return of stock options issued to the individual defendants, and return of the Company’s intellectual property.

On April 10, 2018, Gro-Rite, Naturally Beautiful and Whitetown Realty (“Whitetown Realty” and collectively, the “Whitetown Realty Plaintiffs”) filed a lawsuit in the Superior Court of New Jersey Law Division, Morris County against the Company and Edible Garden alleging, among other things, that Edible Garden owes certain amounts to Gro-Rite under a Marketing and Distribution Agreement between Edible Garden and Gro-Rite, dated May 7, 2013, and Naturally Beautiful under a Marketing and Distribution Agreement between Edible Garden and Naturally Beautiful, dated May 13, 2013 (collectively, the “Marketing and Distribution Agreements”), and that Edible Garden owes certain amounts to Whitetown Realty under the Lease between Whitetown Realty and Edible Garden, dated January 1, 2015 (the “Lease”). The Whitetown Realty Plaintiffs are seeking, among other things, compensatory damages for the amounts claimed are owed and attorneys’ fees and costs. The Company believes that Edible Garden does not owe any payments under the Marketing and Distribution Agreements or the Lease. The Company disputes the Whitetown Realty Plaintiffs’ allegations in the lawsuit and intends to vigorously defend itself. Accordingly, on May 18, 2018, the Company and Edible Garden filed an answer denying the allegations of the Whitetown Realty plaintiffs.  In that same pleading, Edible Garden filed a counterclaim against Naturally Beautiful and Gro-Rite asserting claims for breach of contract, breach of the implied covenant of good faith and fair dealing, unjust enrichment, trademark infringement/unfair competition, and tortious interference with contractual relations.  Edible Garden also filed a third-party complaint against previously unidentified defendants John Doe Entities 1-10 and John Doe Individuals 1-10 arising from the wrongful misappropriation and pirating of electricity from the Edible Garden facility located at 283 Route 519, Belvidere, New Jersey.  That third-party complaint alleges claims for unjust enrichment, tortious interference with contractual relations and conversion.  On June 8, 2018, Edible Garden filed an amended counterclaim adding a count for conversion against Naturally Beautiful and Gro-Rite.  On June 12, 2018, Edible Garden Corp. filed an amended third-party complaint adding Gerda Vande Vrede as a named third-party defendant.  On June 13, 2018, Gro-Rite and Naturally Beautiful filed an answer to Edible Garden’s amended counterclaim and Gerda Vande Vrede filed an answer to Edible Garden’s amended third-party complaint denying the allegations asserted against them.  No counterclaims, crossclaims or fourth party complaints were filed on behalf of Gerda Vande Vrede, Naturally Beautiful or Gro-Rite.

On April 13, 2018, Edible Garden Corp. filed a lawsuit in the Superior Court of New Jersey Chancery Division, Warren County against Whitetown Realty in response to a letter from a law firm representing Whitetown Realty alleging Edible Garden was in default of the Lease. Edible Garden is seeking declaratory and equitable relief to prevent Whitetown Realty from terminating the Lease and for attorneys’ fees and costs. The Company believes that Edible Garden has made all payments due to Whitetown Realty under the Lease and maintains Edible Garden is not in default of the Lease. On April 23, 2018, by order of the assignment judge of Warren County, the lawsuit was transferred to Morris County and consolidated with the April 10, 2018 lawsuit previously filed by Gro-Rite, Naturally Beautiful and Whitetown Realty in the Superior Court of New Jersey, Law Division, Morris County.  On June 13, 2018, Whitetown Realty filed its answer to the Edible Garden Complaint.  In that answer, Whitetown Realty denies that Edible Garden is entitled to the declaratory and equitable relief that Edible Garden requested.  No counterclaim was filed by Whitetown Realty.

On April 11, 2018, Kenneth Vande Vrede, Michael Vande Vrede and Steven Vande Vrede (collectively, the “Vande Vrede Brothers”) filed a lawsuit in the Superior Court of New Jersey Law Division, Warren County against the Company and Edible Garden alleging, among other things, that the Company and Edible Garden improperly suspended the Vande Vrede Brothers from their positions with the Company and Edible Garden. The Vande Vrede Brothers were seeking, among other things, a declaratory judgment that they did not violate their fiduciary duties owed to the Company or Edible Garden and reinstating the Vande Vrede Brothers to their status with the Company and Edible Garden prior to their suspensions and attorneys’ fees and costs. The original complaint in this matter was never served, and on June 12, 2018, the Vande Vrede Brothers, and now David Vande Vrede, Daniel Vande Vrede, Beverly Willekes, and Whitetown Realty filed an amended complaint against Terra Tech, Edible Garden, Derek Peterson, Michael James, and Michael Nahass.  The Company filed a pre-answer motion to dismiss the amended complaint, arguing that any of the plaintiffs’ claims that relate to the Share Exchange Agreement, belong in the already existing lawsuit in California, and any of the plaintiffs’ claims that relate to the lease, belong in the already existing lawsuits in New Jersey.  The Company disputes the Vande Vredes’ allegations in the lawsuit and intends to vigorously defend itself.

29
Table of Contents

  

NOTE 1617 – SUBSEQUENT EVENTS

 

Certificate of Amendment to the Certificate of Designation of the Company’s Series B Preferred StockEquity Financing Facility

 

On July 26, 2017,25, 2018, the Company filedissued a Certificate of Amendment$5,000,000 convertible note to an accredited investor pursuant to the Certificate2018 Master Securities Purchase Agreement. The convertible note matures in January 25, 2020 and accrues interest at a rate of Designation of the Company’s Series B Preferred Stock (the “Amendment”) with the Secretary of State of the State of Nevada to provide for an adjustment of the Conversion Rate of the Company’s Series B Preferred Stock in the event of a reverse stock split or combination in the same ratio as the Company’s common stock. A copy of the Amendment was filed as Exhibit 3.14 to the Company’s Current Report on Form 8-K dated July 26, 2017.7.5% per year.

 

Put on Equity Financing Facility

Subsequent to June 30, 2017,On July 25, 2018, the Company sold 5,519,660 shares of common stock for the net amount of $1,250,000 pursuant to an equity financing facilityentered into a Securities Purchase Agreement with an accredited investor.investor and issued a $150,000 convertible note. The convertible note matures in January 25, 2019 and accrues interest at a rate of 3.0% per year.

 

Debt and Interest Converted into Equity

 

Subsequent to June 30, 2017,2018, senior convertible promissory notes and accrued interest issued under the 2018 Master Securities Purchase Agreement, in the amount of $2,092,492$3,000,000 and $35,938, respectively, were converted into 15,738,4631,932,888 shares of common stock.

 

Employee Stock-Based CompensationOption Issuances

 

Subsequent to June 30, 2017,In July 2018, the Company issued 117,648 shares of common stock for employee stock-based compensation.945,000 options which vest quarterly over 3 years to various directors and executives.

  

Other

On July 26, 2018, the Company received approvals from local authorities for the change of ownership in NuLeaf. As a result, the notes receivable balance at June 30, 2018 was converted into a 50% ownership interest in NuLeaf in July 2018. See “Note 6 – Notes Receivable” for additional disclosure.

On July 26, 2018, the Company announced that it has secured a 25% ownership stake in The Healing Tree Collective, Inc., a cannabis dispensary operator based in California. On July 23, 2018, The Healing Tree Collective, Inc. was awarded a retail permit associated with a facility on W. Pendleton Ave, Santa Ana, by the City of Santa Ana. The remaining 75% of The Healing Tree Collective, Inc. and therefore the associated permit, is held by other members of The Healing Tree Collective, Inc., with whom the Company partnered in order to complete the permit application process. Under the terms of the agreement between the Company and the other members of The Healing Tree Collective, Inc, the Company covered the costs of the permit application and Black Oak, will be responsible for managing all of the facility’s operations, including hiring decisions. The facility is located at 3222 W. Pendleton Ave, Santa Ana, California, an area of Santa Ana in which the Company did not previously have a presence.

On July 24, 2018, the Company announced it has been granted two permits by the City of Santa Ana to operate one retail dispensary on Dyer Road and one on Carnegie Avenue in Santa Ana, California. The first dispensary will be located at 620 East Dyer Road, with plans to become a fully vertical cannabis complex. The second dispensary will be located at 1815 E. Carnegie Avenue.

On July 6, 2018, MediFarm LLC, a wholly-owned subsidiary of the Company, entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Exhale Brands Nevada III, LLC (the “Purchaser”) pursuant to which the Company agreed to sell and the Purchaser agreed to purchase substantially all of the assets of the Company related to the Company’s dispensary located at 1921 Western Ave., Las Vegas, NV 89102 (the “Business”). See “Note 4 - Assets Held for Sale” for additional disclosure.

On July 30, 2018, the Company entered into Independent Director Agreements with Steven J. Ross (the “Ross Agreement”) and Alan Gladstone (the “Gladstone Agreement”).

 
2530
 
Table of Contents

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSOPERATIONS..

 

FORWARD-LOOKING STATEMENTS

 

In addition to historical information, this Quarterly Report on Form 10-Q may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which provides a “safe harbor” for forward-looking statements made by us. All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, beliefs, business strategies, future events, business conditions, results of operations, financial position, business outlook, business trends, and other information, may be forward-looking statements. Words such as “might,” “will,” “may,” “should,” “estimates,” “expects,” “continues,” “contemplates,” “anticipates,” “projects,” “plans,” “potential,” “predicts,” “intends,” “believes,” “forecasts,” “future,” and variations of such words or similar expressions are intended to identify forward-looking statements. The forward-looking statements are not historical facts, and are based upon our current expectations, beliefs, estimates and projections, and various assumptions, many of which, by their nature, are inherently uncertain and beyond our control. Our expectations, beliefs, estimates, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, estimates, and projections will occur or can be can achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements.

 

There are a number of risks, uncertainties, and other important factors, many of which are beyond our control, that could cause actual results to differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. Such risks, uncertainties, and other important factors that could cause actual results to differ include, among others, the risk, uncertainties and factors set forth under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, filed2017 and in other filings we make from time to time with the U.S. Securities and Exchange Commission (the “SEC”(“SEC”), and in this report, as such risk factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov..

  

We caution you that the risks, uncertainties, and other factors set forth in our periodic filings with the SEC may not contain all of the risks, uncertainties, and other factors that are important to you. In addition, we cannot assure you that we will realize the results, benefits, or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected. There can be no assurance that: (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct, or (iv) our strategy, which is based in part on this analysis, will be successful. All forward-looking statements in this report apply only as of the date of the report or as of the date they were made and, except as required by applicable law, we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise.

 

COMPANY OVERVIEWCompany Overview

Terra Tech is a holding company with the following subsidiaries:

·Edible Garden Corp., a Nevada corporation (“Edible Garden”);

·MediFarm, LLC, a Nevada limited liability company (“MediFarm”);

·MediFarm I, LLC, a Nevada limited liability company (“MediFarm I”);

·MediFarm I Real Estate, LLC, a Nevada limited liability company (“MediFarm I RE”);

·MediFarm II, LLC, a Nevada limited liability company (“MediFarm II”);

·IVXX, LLC, a Nevada limited liability company (“IVXX LLC”);

·IVXX, Inc., a California corporation (“IVXX Inc.”; together with IVXX LLC, “IVXX”);

·Blüm San Leandro, a California corporation (“Blüm San Leandro”);

·Black Oak Gallery, a California corporation (“Black Oak”);

·GrowOp Technology Ltd., a Nevada corporation (“GrowOp Technology”); and

·EG Transportation, LLC, a Nevada limited liability company (“EG Transportation”).

26
Table of Contents

 

Our corporate headquarters is located at 2040 Main Street, Suite 225, Irvine, California 92614 and our telephone number is (855) 447-6967. Our website addresses are as follows: www.terratechcorp.com, www.blumoak.com, www.letsblum.com, www.ivxx.com, and www.ediblegarden.com. No information available on or through our websites shall be deemed to be incorporated into this QuarterlyAnnual Report on Form 10-Q.10-K. Our common stock, par value $0.001 (the “Common Stock”), is quoted on the OTC Markets Group, Inc.’s OTCQX tier under the symbol “TRTC.“TRTCD.

31
Table of Contents

 

History and Background

Our original business was developing a software program that would allow for automatic call processing through voice-over-Internet protocol, or “VoIP”, technology. Our operations were limited to capital formation, organization, and development of our business plan and target customer market. We generated no revenue.Recent Developments

 

On February 9, 2012,March 12, 2018, we completedimplemented a reverse-triangular merger with GrowOp Technology whereby we acquired all1-for-15 reverse stock split of our common stock (the “Reverse Stock Split”). The Reverse Stock Split became effective in the issued and outstanding sharesstock market upon commencement of GrowOp Technology.trading on March 13, 2018. As a result of the merger, GrowOp Technology becameReverse Stock Split, every fifteen shares of our wholly-owned subsidiary. FollowingPre-Reverse Stock Split common stock were combined and reclassified into one share of our common stock. No fractional shares were issued in connection with the merger, we ceasedReverse Stock Split, and any fractional shares were rounded up to the nearest whole share. The number of shares of common stock subject to outstanding options, warrants and convertible securities were also reduced by a factor of fifteen as of March 13, 2018. All historical share and per share amounts reflected throughout this report have been adjusted to reflect the Reverse Stock Split. The authorized number of shares and the par value per share of our prior operations and are now solely a holding company with seven wholly-owned subsidiaries. We also own interests in four other subsidiaries.common stock were not affected by the Reverse Stock Split.

 

Our Business

 

We are a vertically integrated cannabis-focused agricultureretail, production and cultivation company, that is committed to cultivating andwith an emphasis on providing the highest quality of medical and adult use cannabis as well as other agricultural products, such asproducts. We also hold an exclusive patent on an organic antioxidant rich Superleaf lettuce and sell living herbs and leafy greens that are grown using classic Dutch hydroponic farming methods.

 

Through Black Oak, we operate a medical marijuana retail dispensary, a medical marijuana cultivation, andWe have a second medical marijuana cultivation facility under construction (the “Hegenberger facility”), allpresence in Oakland, California. Through MediFarm, MediFarm I, and MediFarm II (together “MediFarm”), we operate four retail medical marijuana dispensary facilities inthree states (California, Nevada and New Jersey) and currently have in various stages of construction medical marijuana cultivation and production facilities in Nevada. Through MediFarm I RE, we own the real property in Nevada on which we plan to build a medical marijuana dispensary of which we are in the planning phase. All of our retail dispensariescannabis operations in California and NevadaNevada. Our cannabis dispensaries operate under the name Blüm, whichm. Our cannabis dispensaries offer a broad selection of medical and adult use cannabis products including flowers, concentrates and edibles. Through

In California, we have two dispensaries, one under Black Oak in Oakland, California and one under MediFarm SoCal in Santa Ana, California, which sell quality medical and adult use cannabis products. We are currently in various stages of construction in both states as we are rapidly expanding our commercial footprint focusing on building additional retail, cultivation and production locations for medical and adult use cannabis. The Hegenberger cultivation facility in Oakland under Black Oak is expected to be complete by the third quarter of 2018, with additional medical and adult use locations under Dyer and Carnegie in which we own the real property. We have received provisional permits to operate a dispensary and production facility in the city of San Leandro, California under Blüm San Leandro; and upon project completion and inspection, to receive final operating permits.

In Nevada, we have four dispensaries, three under MediFarm in Las Vegas and one under MediFarm I in Reno, which sell quality medical and adult use cannabis products. We own real property in Reno under MediFarm I RE, on which MediFarm I operates its dispensary. Under MediFarm II, we are constructing a state of the art cultivation and production facility, which will produce our IVXX we produceproprietary brand of cannabis flowers and sellcannabis extracted products available throughout Nevada.

We have access to wide consumer markets for cannabis in both Nevada and California for which our focus is on building a brand portfolio of a line of medicalquality IVXX cannabis products. Within our highly advanced and custom designed extraction labs, we produce the purest concentrates and cannabis extracted products including cartridges and vape pens. Our IVXX cannabis flowers as well as a lineare grown under meticulous standards ensuring exceptional quality and consistency.

32
Table of Contents

Founded on the importance of medical cannabis-extractedproviding consumers with healthy and natural products, which include concentrates, cartridges, vape pens and wax products. Through Edible Garden we areis a retailwholesale seller of organic and locally grown hydroponic produce herbs and floralherb products. EG Transportation supports the distribution of Edible Garden products which are distributed throughto major grocery stores such as ShopRite, Walmart, Winn-Dixie, Raley’s,Ahold, Aldi, Meijer, Kroger, and others throughout New Jersey, New York, Delaware, Maine, Maryland, Connecticut, Pennsylvania and the Midwest. EG Transportation is a company in good standing and no operations to date.

 

We have a “rollup” growth strategy, which includes the following components:

 

·

·

With our brand recognition and experienced management team, maximize productivity, provide economies of scale, and increase profitability through our public market vehicle;

·

·

Acquire unique products and niche players where barriers to entry are high and margins are robust, providing them with a broader outlet for their products; and

·

·

Acquire multiple production facilities to capture the market verticalvertically from manufacturing to production up to retail.

Marijuana Industry Overview

Marijuana cultivation refers to the planting, tending, improving and harvesting of the flowering plant Cannabis, primarily for the production and consumption of cannabis flowers, often referred to as “buds”. The cultivation techniques for marijuana cultivation differ than for other purposes such as hemp production and generally references to marijuana cultivation and production do not include hemp.

27
Table of Contents

Cannabis belongs to the genus Cannabis in the family Cannabaceae and for the purposes of production and consumption, includes three species, C. sativa (“Sativa”), C. indica (“Indica”), and C. ruderalis (“Ruderalis”). Sativa and Indica generally grow tall with some varieties reaching approximately four meters. The females produce flowers rich in tetrahydrocannabinol (“THC”). Ruderalis is a short plant and produces trace amounts of THC, but is very rich in cannabidiol (“CBD”) and which is an antagonist (inhibits the physiological action) to THC.

As of May 2017, there are a total of 29 states, plus the District of Columbia, with legislation passed as it relates to medicinal cannabis. These state laws are in direct conflict with the United States Federal Controlled Substances Act (21 U.S.C. § 811) (“CSA”), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug, which is viewed as having a high potential for abuse, has no currently-accepted use for medical treatment in the U.S., and lacks acceptable safety for use under medical supervision.

These 29 states, and the District of Columbia, have adopted laws that exempt patients who use medicinal cannabis under a physician’s supervision from state criminal penalties. These are collectively referred to as the states that have de-criminalized medicinal cannabis, although there is a subtle difference between de-criminalization and legalization, and each state’s laws are different.

The states that have legalized medicinal cannabis are as follows (in alphabetical order):

1. Alaska

11. Maine

21. New York

2. Arizona

12. Maryland

22. North Dakota

3. Arkansas

13. Massachusetts

23. Ohio

4. California

14. Michigan

24. Oregon

5. Colorado

15. Minnesota

25. Pennsylvania

6. Connecticut

16. Montana

26. Rhode Island

7. Delaware

17. Nevada

27. Vermont

8. Florida

18. New Hampshire

28. Washington

9. Hawaii

19. New Jersey

29. West Virginia

10. Illinois

20. New Mexico

 

Medical cannabis decriminalization is generally referredOur business also represents our operating segments. See our Part I, Item 1. Business, “Company Overview” and “Note 15 – Segment Information” to as the removal of all criminal penaltiesour unaudited consolidated financial statements for the private possession and use of cannabis by adults, including cultivation for personal use and casual, nonprofit transfers of small amounts. Legalization is generally referred to as the development of a legally controlled market for cannabis, where consumers purchase from a safe, legal, and regulated source.

The dichotomy between federal and state laws has also limited the access to banking and other financial services by marijuana businesses. Recently the U.S. Department of Justice and the U.S. Department of Treasury issued guidance for banks considering conducting business with marijuana dispensaries in states where those businesses are legal, pursuant to which banks must now file a Marijuana Limited Suspicious Activity Report that states the marijuana business is following the government’s guidelines with regard to revenue that is generated exclusively from legal sales. However, since the same guidance noted that banks could still face prosecution if they provide financial services to marijuana businesses, it has led to the widespread refusal of the banking industry to offer banking services to marijuana businesses operating within state and local laws.

28
Table of Contents

In November 2016, California and Nevada voters both approved marijuana use for adults over the age of 21 without a physician’s prescription or recommendation, so called recreational marijuana, and permitted the cultivation and sale of marijuana, in each case subject to certain limitations. We have obtained the necessary permits and licenses to expand our existing business to cultivate and distribute marijuana in compliance with the laws in the state of Nevada and California. We have received provisional permits to operate a dispensary and production facility in the city of San Leandro, California, and upon project completion and inspection, to receive final operating permits. Although, there is no guarantee that we will be successful in doing so. Despite the changes in state laws, marijuana remains illegal under federal law.

In November 2016, California voters approved Proposition 64, which is also known as the Adult Use of Marijuana Act (“the AUMA”), in a ballot initiative. Among other things, the AUMA makes it legal for adults over the age of 21 to use marijuana and to possess up to 28.5 grams of marijuana flowers and 8 grams of marijuana concentrates. Individuals are also permitted to grow up to six marijuana plants for personal use. In addition, the AUMA establishes a licensing system for businesses to, among other things, cultivate, process and distribute marijuana products under certain conditions. Many of the provisions of the AUMA do not become effective until January 1, 2018 and the California Bureau of Marijuana Control is expected to enact regulations to implement the AUMA by that date.

Nevada voters approved Question 2 in a ballot initiative in November 2016. Among other things, Question 2 makes it legal for adults over the age of 21 to use marijuana and to possess up to one ounce of marijuana flowers and one-eighth of an ounce of marijuana concentrates. Individuals are also permitted to grow up to six marijuana plants for personal use. In addition, Question 2 authorizes businesses to cultivate, process and distribute marijuana products under certain conditions. On June 30, 2017, the State of Nevada Department of Taxation approved our Dual Use Marijuana business licenses. This approval allowed all fourfurther discussion of our Blüm cannabis dispensaries in Nevada to commence sales of cannabis for adult-use beginning on July 1, 2017.

In an effort to provide guidance to federal law enforcement, the Department of Justice (the “DOJ”) has issued Guidance Regarding Marijuana Enforcement to all United States Attorneys in a memorandum from Deputy Attorney General David Ogden on October 19, 2009, in a memorandum from Deputy Attorney General James Cole on June 29, 2011 and in a memorandum from Deputy Attorney General James Cole on August 29, 2013. Each memorandum provides that the DOJ is committed to the enforcement of the CSA, but the DOJ is also committed to using its limited investigative and prosecutorial resources to address the most significant threats in the most effective, consistent, and rational way.

The August 29, 2013 memorandum provides updated guidance to federal prosecutors concerning marijuana enforcement in light of state laws legalizing medical and recreational marijuana possession in small amounts. The memorandum sets forth certain enforcement priorities that are important to the federal government:

·Distribution of marijuana to children;

·Revenue from the sale of marijuana going to criminals;

·Diversion of medical marijuana from states where it is legal to states where it is not;

·Using state authorized marijuana activity as a pretext of other illegal drug activity;

·Preventing violence in the cultivation and distribution of marijuana;

·Preventing drugged driving;

·Growing marijuana on federal property; and

·Preventing possession or use of marijuana on federal property.

The DOJ has not historically devoted resources to prosecuting individuals whose conduct is limited to possession of small amounts of marijuana for use on private property, but has relied on state and local law enforcement to address marijuana activity. In the event the DOJ reverses its stated policy and begins strict enforcement of the CSA in states that have laws legalizing medical marijuana and recreational marijuana in small amounts, there may be a direct and adverse impact to our business and our revenue and profits.

Furthermore, H.R. 83, enacted by Congress on December 16, 2014, provides that none of the funds made available to the DOJ pursuant to the 2015 Consolidated and Further Continuing Appropriations Act may be used to prevent certain states, including Nevada and California, from implementing their own laws that authorized the use, distribution, possession, or cultivation of medical marijuana.

We are monitoring the Trump administration’s, the DOJ’s and Congress’ positions on federal marijuana law and policy. Based on public statements and reports, we understand that certain aspects of those laws and policies are currently under review, but no official changes have been announced. It is possible that certain changes to existing laws or policies could have a negative effect on our business and results of operations.

29
Table of Contents

We currently operate medical marijuana businesses in California and Nevada. Although the possession, cultivation and distribution of marijuana for medical use is permitted in California and Nevada, provided compliance with applicable state and local laws, rules, and regulations, marijuana is illegal under federal law. We believe we operate our business in compliance with applicable Nevada and California law and regulations. Any changes in federal, state or local law enforcement regarding marijuana may affect our ability to operate our business. Strict enforcement of federal law regarding marijuana would likely result in the inability to proceed with our business plans, could expose us to potential criminal liability and could subject our properties to civil forfeiture. Any changes in banking, insurance or other business services may also affect our ability to operate our business.

Our Medical Marijuana Dispensaries, Cultivation and Manufacturing

Black Oak Gallery

On April 1, 2016, we acquired Black Oak, which operates a medical marijuana dispensary in Oakland, California under the name Blüm. Black Oak opened its retail storefront in Oakland, California in November 2012.

Black Oak sells a combination of our own cultivated products as well as high quality name-brand products from outside suppliers. In addition to multiple grades of medical marijuana, Black Oak sells “edibles”, which include cannabis-infused baked goods, chocolates, and candies; cannabis-infused topical products, such as lotions, massage oils and balms; clones of marijuana plants; and numerous kinds of cannabis concentrates, such as hash, shatter and wax.

Black Oak’s target markets are those individuals located in the areas surrounding its dispensary and qualify as “patients” under state and local rules and regulations. Black Oak services approximately 1,000 patients per day and has over 42,000 registered patients. Collectively known as the Blüm Campus, Black Oak’s location consists of a retail dispensary storefront, indoor cultivation area, laboratory and a 20-car capacity parking lot.

During March 2017, we executed a lease for 13,000 square feet of industrial space on over 30,000 square feet of land in Oakland’s industrial corridor. We are in the early stages of construction of the Hegenberger facility. We expect to complete construction by late 2017.

On May 11, 2017, we terminated the Operations and Asset Management Agreement (the “Agreement”) by and among the Company, Black Oak and Platinum Standard, LLC (“Platinum”), dated March 31, 2016. There is no relationship between the Company or its affiliates and Platinum, other than pursuant to the Agreement. Pursuant to the Agreement, the Company hired and appointed Platinum as the operator and asset manager of the Company’s licensed medical cannabis dispensary business located at 578 West Grand Avenue, in the City of Oakland, State of California, commonly known as Blüm Oakland, in exchange for certain payments to be made by the Company to Platinum, all as more fully set forth in the Agreement. We terminated the Agreement as a result of the default by Platinum in the performance of certain of its material obligations under the Agreement. We did not incur any early termination penalty in connection with terminating the Agreement. A copy of the Agreement was filed as Exhibit 10.29 to the Company’s Form 10-Q for the quarterly period ended March 31, 2016. See “Note 9 – Contingent Consideration Liability” for further information.

Blüm San Leandro

We incorporated Blüm San Leandro, a California corporation, a wholly-owned subsidiary, on October 14, 2016. Blüm San Leandro has received the necessary governmental approvals and permitting to operate a medical marijuana dispensary and production facility in San Leandro, California. We have executed a lease for 13,300 square feet of industrial space in San Leandro’s industrial corridor and are in the final planning and design stages of the retail dispensary and production facility. We also plan on incorporating community meeting space at this facility. We expect to complete construction of the dispensary by late 2017 and we expect to complete construction of the production facility and community meeting space by early 2018.

30
Table of Contents

MediFarm, MediFarm I, and MediFarm II

We formed three subsidiaries for the purposes of cultivation or production of medical marijuana and/or operation of dispensary facilities in various locations in Nevada. MediFarm, MediFarm I, and MediFarm II have received four final dispensary licenses, two provisional cultivation licenses and two provisional production licenses from the State of Nevada, and we have received approval from local authorities with respect to all eight of such licenses. The receipt of both the provisional licenses from the State of Nevada and approval from local authorities were necessary to commence the final permitting process for the cultivation and production licenses. The receipt of final permits and licenses was necessary to commence the cultivation and production businesses of MediFarm, MediFarm I, and MediFarm II. Effectuation of the businesses of each of (i) MediFarm, (ii) MediFarm I, and (iii) MediFarm II is also dependent upon the continued legislative authorization of medical marijuana at the state level.

Each subsidiary was formed with different investors, thus necessitating the need for multiple entities with different strategic partners and advisory board members. In addition, we anticipate each subsidiary will service a different geographical market in Nevada. We expect to allocate future business opportunities among MediFarm, MediFarm I, and MediFarm II based on the locations of such opportunities.

We formed MediFarm, LLC on March 19, 2014. We own 60% of the membership interests in MediFarm. The remaining membership interests are owned by Camden Goorjian (20%) and by Richard Vonfeldt (20%), two otherwise unaffiliated individuals. MediFarm has received the necessary governmental approvals and permitting to operate medical marijuana cultivation, production, and/or dispensary facilities in Clark County, Nevada and a medical marijuana dispensary facility in the City of Las Vegas. As of June 30, 2017, MediFarm has three fully operational retail medical marijuana dispensaries in the greater Las Vegas region.

We formed MediFarm I, LLC on July 18, 2014. We own 50% of the membership interests in MediFarm I. The remaining membership interests are owned by Forever Green NV, LLC (50%), an otherwise unaffiliated entity that also owns certain membership interests in MediFarm II. MediFarm I has the necessary governmental approvals and permitting to operate a medical marijuana dispensary in Reno, Nevada. As of June 30, 2017, MediFarm I has one fully operational retail medical marijuana dispensary in Reno, Nevada.

We formed MediFarm II, LLC on July 30, 2014. We own 55% of the membership interests in MediFarm II. The remaining membership interests are owned by Nevada MF, LLC (30%) and by Forever Green NV, LLC (15%), two otherwise unaffiliated entities. Forever Green NV, LLC also owns certain membership interests in MediFarm I. MediFarm II has received provisional licenses from the State of Nevada to operate a medical marijuana cultivation and production facility in Spanish Springs, Nevada.

MediFarm, MediFarm I, and MediFarm II may face substantial competition in the operation of cultivation, production, and dispensary facilities in Nevada. Numerous other companies were also granted licenses, and, therefore, we anticipate that we will face competition with these other companies if such companies operate cultivation, production, and dispensary facilities in and around the locations at which we operate our facilities. Our management has extensive experience in successfully developing, implementing, and operating all facets of equivalent businesses in other markets. We believe this experience will provide MediFarm, MediFarm I, and MediFarm II with a competitive advantage over these other companies.

MediFarm, MediFarm I, and MediFarm II rely on a combination of trademark laws, trade secrets, confidentiality provisions, and other contractual provisions to protect their proprietary rights. MediFarm, MediFarm I, and MediFarm II do not own any patents.

IVXX and IVXX Branded Products

On September 16, 2014, Terra Tech formed IVXX, a wholly-owned subsidiary, for the purposes of producing a line of IVXX branded cannabis flowers as well as a complete line of IVXX branded pure cannabis concentrates including: oils, waxes, shatters, and clears.

31
Table of Contents

The science of cannabis concentrate extraction functions on the solubility of the cannabinoids and other active ingredients in the cannabis plant. Cannabinoids are not water soluble, so to extract them properly, the cannabinoids must be dissolved in a solvent. IVXX utilizes multiple proprietary extraction methods to produce its concentrates in its lab located in Oakland, California. The Company’s extractors process raw cannabis plants and separate the chemical cannabinoids from the cannabis plant material, producing a concentrate. IVXX also sells clothing, apparel, and other various branded products.

IVXX currently sells its branded products at wholesale to multiple medical cannabis dispensaries throughout California. None of IVXX’s products cross state lines. IVXX continues to actively seek opportunities to sell its products to other retailers located throughout the State of California. IVXX anticipates expanding its business into other states in which the sale of marijuana is legally permitted. In order for such expansion to occur, IVXX must secure the necessary licenses and permits required to operate in any given state, the timing and occurrence of which there can be no assurance. Initially, IVXX anticipates selling its products in Nevada in the four dispensaries operated by MediFarm and MediFarm I. They will be produced at our extraction lab operated by MediFarm II once they are issued final permits and commence operations, as to the occurrence of which there can be no assurance.

IVXX’s target markets are those individuals located in the areas surrounding the dispensaries that sell IVXX’s products and that qualify as “patients” under state and local rules and regulations.

IVXX also intends to produce, market and sell their line of IVXX branded cannabis products in the adult use, recreational cannabis markets in both California and Nevada pursuant to Proposition 64 and Question 2, respectively, which made marijuana consumption legal, with certain restrictions and rules, for adults over the age of 21. IVXX is consistently engaged in research and development with respect to increasing the efficiency of the processes used to produce its products, as well as improving the quality of its products for the benefit of its patients.

On May 24, 2017, we announced the launch of a new “Craft Cultivation” model to expand our cultivation capabilities and the signing of our first “Craft Cultivator” in Northern California. This farm, which is approved for up to one full acre (approximately 44,000 square feet) of cannabis cultivation and uses 22,000 square feet of engineered greenhouse space, is estimated to yield approximately one metric ton of our proprietary high grade “IVXX” cannabis on an annual basis.

MediFarm I RE

On October 14, 2015, we formed MediFarm I RE, LLC. We own 50% of the membership interests in MediFarm I RE. The remaining membership interests are owned by Forever Young Investments, LLC (50%), an otherwise unaffiliated entity. MediFarm I RE is a real estate holding company that owns the real property and a building that is situated on such real property, at which a medical marijuana dispensary facility is expected to be located. This facility is in the early stages of planning. It is our intention that MediFarm I will operate the medical marijuana dispensary.

Herbs and Produce Products

Edible Garden

Edible Garden was incorporated on April 9, 2013. Edible Garden is a retail seller of locally grown hydroponic produce, herbs, and floral products that are distributed throughout the Northeast and Midwest United States. Currently, Edible Garden’s products are sold at approximately 1,800 retailers throughout these markets. Most of the produce and herbs grown by Edible Garden are certified organic. Our target customers are those individuals seeking organic and fresh produce locally grown using environmentally sustainable methods.

Pursuant to letter agreements with Gro-Rite Inc., a New Jersey corporation, and Heartland Growers Inc. (collectively the “Farmers”), have agreed to cultivate the various parts of the line of Edible Garden produce to be sold into the retail grocery channel. Pursuant to the terms of the agreements, Edible Garden will manage the marketing and sales, while the Farmers will be responsible for the cultivation, packaging, and shipping of the product for retail sale under the Edible Garden brand. The terms of the agreements are now month-to-month.

32
Table of Contents

There are numerous growers that are available to us, and therefore, we are not limited in the number of growers available nor are we dependent on any one grower. We completed construction of a greenhouse structure in 2014, which can be used to grow plants to satisfy selling demands; however, we may incur additional freight costs to distribute these plants until growers are replaced.

Edible Garden’s main competitors are Shenandoah Growers and Sun Aqua Farms. To a lesser extent, Edible Garden competes with Green Giant, Del Monte, Rock Hedge Herbs, and Infinite Herbs. Edible Garden is an up and coming brand that has increased its retailers to approximately 1,800 retail sellers since we acquired Edible Garden in March 2013. Edible Garden believes the following three factors set it apart from its competitors: (1) its branding and marketing displays, which are predominately placed in high traffic areas on its proprietary racks; (2) it uses proprietary strands and seeds for its produce and its methodology for growing such produce; and (3) all of its produce is hydroponically grown and sold “alive” (i.e., the produce is sold “rooted”).

Edible Garden relies on a combination of trademark laws, trade secrets, confidentiality provisions, and other contractual provisions to protect its proprietary rights, which are primarily its brand names, marks, and proprietary pods and seeds. Edible Garden owns trademarks, but does not own any patents. Edible Garden signed an exclusive license agreement with Nutrasorb LLC, a spin-off from Rutgers University, to grow and commercialize nutritionally-enhanced lettuce varieties. Under the terms of the agreement, Edible Garden has the right to grow and sell Green and Red Superleaf Lettuce across the North American and European continents as well as Australia. With five times more antioxidants than ordinary lettuce, the produce is high in vitamins A and C, magnesium, iron and potassium contents. It also has high levels of fiber and chlorogenic acid for superior digestion. These nutritionally-enhanced, proprietary Green and Red Superleaf Lettuces were developed by scientists at Rutgers University following years of intensive research. Edible Garden pays a license fee to Nutrasorb, LLC for each unit sold.

Edible Garden’s produce is Global Food Safety Initiative certified. Edible Garden also obtained certain organic certifications for its products. No other governmental regulations or approvals are needed or affect its business.

Edible Garden’s research and development activities have primarily focused on developing and testing new pods and seeds, as well as different fertilizers, nutrient blends, and lighting.segments.

 

Our Operations

 

We are organized into two reportable segments:

 

·

·

Herbs and Produce Products – Includes herbs and leafy greens that are grown using classic Dutch hydroponic farming methods; and

·

·

Cannabis Dispensary, Cultivation and Production – Includes cannabis-focused retail, cultivation and production.

Our segment net revenue and contributions to consolidated net revenue for each of the three and six months ended June 30, 2018 and 2017 were as follows:

 

 

Total Revenue

 

 

Percentage of Total Revenue

 

 

 

Three Months Ended

 

 

Three Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Herbs and Produce Products

 

$1,502,789

 

 

$1,777,067

 

 

 

17.24%

 

 

22.66%

Cannabis Dispensary, Cultivation and Production

 

 

7,203,971

 

 

 

6,049,319

 

 

 

82.63%

 

 

77.13%

Other and Eliminations

 

 

11,417

 

 

 

16,487

 

 

 

0.13%

 

 

0.21%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

$8,718,177

 

 

$7,842,873

 

 

 

100.00%

 

 

100.00%

33
Table of Contents

 

 

Total Revenue

 

 

Percentage of Total Revenue

 

 

 

Six Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2018

 

 

2017

 

 

2018

 

 

2017

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Herbs and Produce Products

 

$2,786,690

 

 

$2,694,210

 

 

 

16.08%

 

 

18.37%

Cannabis Dispensary, Cultivation and Production

 

 

14,518,525

 

 

 

11,936,357

 

 

 

83.76%

 

 

81.38%

Other and Eliminations

 

 

28,328

 

 

 

36,762

 

 

 

0.16%

 

 

0.25%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

$17,333,543

 

 

$14,667,329

 

 

 

100.00%

 

 

100.00%
 

See “Note 2 – Summary of Significant Accounting Policies” to our unaudited consolidated financial statements for financial information about our segments. See also “Item 1A. Risk Factors” below for a discussion of certain risks associated with our operations.

 

Herbs and Produce Products

 

Either independently or in conjunction with third parties, we are a retail seller of locally grown hydroponic herbs produce, and floral products,produce, which are distributed through major grocery stores throughout the East, West and Midwest regions of the U.S.

 

Cannabis Dispensary, Cultivation and Production

 

Either independently or in conjunction with third parties, we operate medical marijuanacannabis retail and adult use dispensaries and a medical marijuanacannabis and adult use cultivation in California. In addition, we operate four retail medical marijuanaand adult use cannabis dispensary facilities in Nevada, and have in various stages of construction, medical marijuanacannabis and adult use cultivation and production facilities in Nevada. We own real property in Nevada on which we plan to build a medical marijuanaand adult use cannabis dispensary. All of our retail dispensaries in California and Nevada offer a broad selection of medical and adult use cannabis products including flowers, concentrates and edibles. We also produce and sell a line of medical and adult use cannabis flowers, as well as a line of medical and adult use cannabis-extracted products, which include concentrates, cartridges, vape pens and wax products.

 
33
Table of Contents

Employees

As of the date of this Quarterly Report on Form 10-Q, we had approximately 255 employees.

  

RESULTS OF OPERATIONS

 

Three Months Ended June 30, 20172018 Compared to Three Months Ended June 30, 20162017

 

Revenues

 

For the three months ended June 30, 2017,2018, we generated revenues of $7.84$8.72 million, compared to $9.70$7.84 million for the three months ended June 30, 2016, a decrease2017, an increase of $1.86$0.88 million or 19.211.2 percent. The decreaseincrease was primarily due to: (i) $2.43 million higher revenues generated by the Nevada MediFarm dispensaries primarily due to the implementation of adult use sales in July 2017; (ii) $0.45 million in revenues from floral salesgenerated by MediFarm SoCal which started operations in September 2017; (iii) $0.93 million decrease in IVXX revenues due to the production facilities of IVXX are currently being relocated to an upgraded facility that will facilitate the increase in production and achieve greater distribution throughout California. Project completion is estimated to be in the fourth quarter of 2018; and (iv) $0.82 million decrease in Black Oak revenues resulting from higher California state excise tax rates effective January 1, 2018, which negatively impacted demand, and a contract that expired at December 31, 2016. The floral revenues were $4.40$0.21 million for the three months ended June 30, 2016 versus zero for the three months ended June 30, 2017. The decrease was partially offset by increased revenue generated by: (i) the Black Oak, MediFarm and MediFarm I dispensaries; (ii) IVXX from the sale of its cannabis products; and (iii)in Edible Garden from the sale of its herbs and produce products.Garden. At this stage in our development, revenues are not yet sufficient to cover ongoing operating expenses.

Cost of Goods Sold

For the three months ended June 30, 2017, cost of goods sold was $6.34 million, compared to $8.15 million for the three months ended June 30, 2016, a decrease of $1.81 million or 22.2%. The decrease in cost of goods sold was attributable to: (i) a decrease of $4.19 million from the herbs and produce segment, which had $1.33 million and $5.52 million cost of goods sold for the three months ended June 30, 2017 and 2016, respectively; and (ii) an increase of $2.41 million from the cannabis segment, which had $5.01 million and $2.60 million cost of goods sold for the three months ended June 30, 2017 and 2016, respectively. The cannabis segment increase was related to two additional MediFarm dispensaries and one additional MediFarm I dispensary that were open during the three months ended June 30, 2017 versus not being open during the three months ended June 30, 2016. The herbs and produce segment decrease was related to the expiration of the floral product contract.

Gross Profit

Our gross profit for the three months ended June 30, 2017 was $1.51 million, compared to a gross profit of $1.55 million for the three months ended June 30, 2016, a decrease of $41,000 or 2.6 percent. Our gross margin percentage for the three months ended June 30, 2017 was 19.2 percent, compared to 15.9 percent for the three months ended June 30, 2016. The increase in gross margin percentage was attributable to: (i) the cannabis segment, which had $1.04 million and $1.17 million gross profit for the three months ended June 30, 2017 and 2016, respectively, or 17.2 percent and 31.1 percent gross margin for the three months ended June 30, 2017 and 2016, respectively; and (ii) the herbs and produce segment, which had $451,000 and $356,000 gross profit for the three months ended June 30, 2017 and 2016, respectively, or 25.4 percent and 6.1 percent gross margin for the three months ended June 30, 2017 and 2016, respectively. The cannabis segment decrease was related to two additional MediFarm dispensaries and one additional MediFarm I dispensary that were open during the three months ended June 30, 2017 versus not being open during the three months ended June 30, 2016. The cannabis products gross margin percentage decreased due to discounting of the products sold at the new dispensaries in an effort to gain market share. The herbs and produce segment increase was related to the expiration of the floral product contract.

 
 
34
 
Table of Contents

 

Gross Profit

Our gross profit for the three months ended June 30, 2018 was $2.21 million, compared to a gross profit of $1.51 million for the three months ended June 30, 2017, an increase of $0.70 million or 46.6 percent. Our gross margin percentage for the three months ended June 30, 2018 was 25.3 percent, compared to 19.2 percent for the three months ended June 30, 2017. The increase was primarily attributable to the cannabis segment, which increased by $0.61 million primarily resulting from higher level of revenue to cover fixed overhead included in cost of goods sold.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended June 30, 2018 were $8.00 million, compared to $6.03 million for the three months ended June 30, 2017, an increase of $1.97 million or 32.7 percent. The increase was primarily due to: (i) a $0.95 million increase in salaries and related payroll taxes due to new hires in the compliance department and overall headcount increases; (ii) a $0.59 million increase in stock compensation related to employee bonuses; and (iii) a $0.35 million increase in other professional fees related to outside consultants implementing new accounting systems.

Operating Income (Loss)

We realized an operating loss of $5.79 million for the three months ended June 30, 2018, compared to an operating loss of $4.52 million for the three months ended June 30, 2017, an increase of approximately $1.27 million or 28.1 percent.

Other Income (Expense)

Other expense for the three months ended June 30, 2018 was $5.53 million, compared to other income of $3.62 million for the three months ended June 30, 2017, a decrease of $9.15 million or 252.9 percent. This decrease was primarily attributable to: (i) a gain on the settlement of the contingent consideration of $4.99 million from Black Oak during the three months ended June 30, 2017, compared to zero in the three months ended June 30, 2018; (ii) an increase in loss on fair market valuation of derivatives of $2.64 million; and (iii) an increase in loss on extinguishment of debt of $1.49 million. 

Net Loss Attributable to Terra Tech Corp.

We incurred a net loss of $11.43 million, or $0.17 per share, for the three months ended June 30, 2018, compared to a net loss of $0.45 million, or $0.01 per share, for the three months ended June 30, 2017.

Management will continue its efforts to lower operating expenses and increase revenue. We will continue to invest in further expanding our operations and a comprehensive marketing campaign with the goal of accelerating the education of potential clients and promoting our name and our products. Given the fact that most of the operating expenses are fixed or have a quasi-fixed character, management expects that, as revenue increases, those expenses, as a percentage of revenue, will significantly decrease. Nevertheless, there can be no assurance that we will be able to increase our revenues in succeeding quarters.

Six Months Ended June 30, 2018 Compared to Six Months Ended June 30, 2017

Revenues

For the six months ended June 30, 2018, we generated revenues of $17.33 million, compared to $14.67 million for the six months ended June 30, 2017, an increase of $2.67 million or 18.2 percent. The increase was primarily due to: (i) $4.96 million higher revenues generated by the Nevada MediFarm dispensaries primarily due to the implementation of adult use sales in July 2017; (ii) $1.01 million revenue generated by MediFarm SoCal which started operations in September 2017; (iii) $2.40 million decrease in IVXX revenues due to the production facilities of IVXX are currently being relocated to an upgraded facility that will facilitate the increase in production and achieve greater distribution throughout California. Project completion is estimated to be in the fourth quarter of 2018; and (iv) $0.99 million decrease in Black Oak revenues resulting from higher California state excise tax rates effective January 1, 2018, which negatively impacted demand. At this stage in our development, revenues are not yet sufficient to cover ongoing operating expenses.

35
Table of Contents

Gross Profit

Our gross profit for the six months ended June 30, 2018 was $3.86 million, compared to a gross profit of $1.87 million for the six months ended June 30, 2017, an increase of $1.99 million or 106.7 percent. Our gross margin percentage for the six months ended June 30, 2018 was 22.3 percent, compared to 12.7 percent for the six months ended June 30, 2017. The increase in gross margin percentage was attributable to: (i) the cannabis segment, which had $3.26 million and $1.43 million gross profit for the six months ended June 30, 2018 and 2017, respectively, or 22.5 percent and 12.0 percent gross margin for the six months ended June 30, 2018 and 2017, respectively; and (ii) the herbs and produce segment, which had $0.56 million and $0.40 million gross profit for the six months ended June 30, 2018 and 2017, respectively, or 20.3 percent and 14.8 percent gross margin for the six months ended June 30, 2018 and 2017, respectively. The cannabis segment increase was primarily related to the gross profit margins generated from the Nevada MediFarm dispensaries due to the implementation of adult use sales in July 2017.

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses for the threesix months ended June 30, 2018 were $16.42 million, compared to $12.42 million for the six months ended June 30, 2017, were $6.03 million, compared to $5.36 million for the three months ended June 30, 2016, an increase of $665,000$4.01 million or 12.432.3 percent. The increase was primarily due to: (i) a $1.94 million increase in salaries and related payroll taxes due to salaries fornew hires in the MediFarm dispensariescompliance department and overall headcount increases; (ii) a $1.04 million increase in Las Vegas, Nevada.stock compensation related to employee bonuses; (iii) a $0.51 million increase in license, permits and property taxes due to higher revenue generated from the cannabis segment; and (iv) a $0.37 million increase in depreciation and amortization due to new assets placed in service.

 

Operating Income (Loss)

 

We realized an operating loss of $4.52$12.57 million for the threesix months ended June 30, 2017,2018, compared to an operating loss of $3.82$10.55 million for the threesix months ended June 30, 2016,2017, an increase of $706,000$2.02 million or 18.519.1 percent.

 

Other Income (Expense)

 

Other incomeexpense for the threesix months ended June 30, 2018 was $8.71 million, compared to $0.93 million for the six months ended June 30, 2017, was $3.62 million, compared to other expense of $973,000 for the three months ended June 30, 2016, an increase of $4.59 million.$7.78 million or 836.6 percent. This increase was primarily attributable to: (i) a gain on the settlement of the contingent consideration of $4.99 million gain on settlement of contingent consideration related to thefrom Black Oak acquisition (see “Note 9 – Contingent Consideration Liability” for further information);during the six months ended June 30, 2017, compared to zero in the six months ended June 30, 2018; (ii) a $4.43 million loss on fair market valuation of contingent consideration;consideration during the six months ended June 30, 2017, compared to zero in the six months ended June 30, 2018; (iii) an increase in loss on extinguishment of debt of $1.64 million, which was $1.64 million for the three months ended June 30, 2017, compared to zero in the prior year period;$5.18 million; and (iv) an increase in amortization of debt discount of $298,000, which was $516,000 for the three months ended June 30, 2017, compared to $218,000 in the prior year period; (v) a decrease in gain (loss) on fair market valuation of derivatives of $1.19 million, which was a gain of $987,000 for the three months ended June 30, 2017, compared to a loss of $206,000 in the prior year period; and (vi) a decrease in loss from derivatives issued with debt greater than debt carrying value of $488,000, which was zero for the three months ended June 30, 2017, compared to $488,000 in the prior year period.$1.97 million. 

 

Net Loss Attributable to Terra Tech Corp.

 

We incurred a net loss attributable to Terra Tech Corp. of $454,000,$21.46 million, or $0.00$0.32 per share, for the threesix months ended June 30, 2017,2018, compared to a net loss attributable to Terra Tech Corp. of $4.93$10.57 million, or $0.01$0.28 per share, for the threesix months ended June 30, 2016. The primary reasons for the decrease were a decrease in revenue, an increase in selling, general and administrative expenses, and an increase in gain on settlement of contingent consideration during the three months ended June 30, 2017, compared to the prior year period.2017.

 

Management will continue its efforts to lower operating expenses and increase revenue. We will continue to invest in further expanding our operations and a comprehensive marketing campaign with the goal of accelerating the education of potential clients and promoting our name and our products. Given the fact that most of the operating expenses are fixed or have a quasi-fixed character, management expects that, as revenue increases, those expenses, as a percentage of revenue, will significantly decrease. Nevertheless, there can be no assurance that we will be able to increase our revenues in succeeding quarters.

 
 
35
Table of Contents

Six Months Ended June 30, 2017 Compared to Six Months Ended June 30, 2016

Revenues

For the six months ended June 30, 2017, we generated revenues of $14.67 million, compared to $11.25 million for the six months ended June 30, 2016, an increase of $3.42 million or 30.4 percent. The increase was primarily due to revenue generated by: (i) the Black Oak, MediFarm and MediFarm I dispensaries; (ii) IVXX from the sale of its cannabis products; and (iii) Edible Garden from the sale of its herbs and produce products; partially offset by a decrease in revenues from floral sales resulting from the expiration of a contract for floral product that expired at December 31, 2016. The floral revenues were $4.79 million for the six months ended June 30, 2016 versus zero for the six months ended June 30, 2017. At this stage in our development, revenues are not yet sufficient to cover ongoing operating expenses.

Cost of Goods Sold

For the six months ended June 30, 2017, cost of goods sold was $12.80 million, compared to $9.69 million for the six months ended June 30, 2016, an increase of $3.11 million or 32.1%. The increase in cost of goods sold was attributable to: (i) an increase of $7.70 million from the cannabis segment, which had $10.51 million and $2.81 million cost of goods sold for the six months ended June 30, 2017 and 2016, respectively; and (ii) a decrease of $4.54 million from the herbs and produce segment, which had $2.30 million and $6.84 million cost of goods sold for the six months ended June 30, 2017 and 2016, respectively. The cannabis segment increase was related to: (i) a full six months of cost of goods sold for Black Oak during the six months ended June 30, 2017 versus cost of goods sold for only three months of ownership for the six months ended June 30, 2016; and (ii) two additional MediFarm dispensaries and one additional MediFarm I dispensary that were open during the six months ended June 30, 2017 versus not being open during the six months ended June 30, 2016. The herbs and produce segment decrease was related to the expiration of the floral product contract.

Gross Profit

Our gross profit for the six months ended June 30, 2017 was $1.87 million, compared to a gross profit of $1.56 million for the six months ended June 30, 2016, an increase of $304,000 or 19.5 percent. Our gross margin percentage for the six months ended June 30, 2017 was 12.7 percent, compared to 13.9 percent for the six months ended June 30, 2016. The decrease in gross margin percentage was attributable to: (i) the cannabis segment, which had $1.43 million and $1.09 million gross profit for the six months ended June 30, 2017 and 2016, respectively, or 12.0 percent and 28.0 percent gross margin for the six months ended June 30, 2017 and 2016, respectively; and (ii) the herbs and produce segment, which had $399,000 and $437,000 gross profit for the six months ended June 30, 2017 and 2016, respectively, or 14.8 percent and 6.0 percent gross margin for the six months ended June 30, 2017 and 2016, respectively. The cannabis segment increase was related to: (i) a full six months of gross profit for Black Oak during the six months ended June 30, 2017 versus only three months of ownership that contributed to gross profit for the six months ended June 30, 2016; and (ii) two additional MediFarm dispensaries and one additional MediFarm I dispensary that were open and contributed to gross profit for the six months ended June 30, 2017 versus not being open during the six months ended June 30, 2016. The cannabis products gross margin percentage decreased due to discounting of the products sold at the new dispensaries in an effort to gain market share. The herbs and produce segment decrease in gross profit was partially offset by an increase in gross margin percentage related to the expiration of the floral products contract.

36
Table of Contents

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the six months ended June 30, 2017 were $12.42 million, compared to $7.29 million for the six months ended June 30, 2016, an increase of $5.13 million or 70.4 percent. The increase was primarily due to two factors: (i) an increase in salaries and wages for operations at the MediFarm dispensaries, which includes $1.36 million of stock compensation expense issued to employees during the six months ended June 30, 2017, compared to no stock compensation issued to employees during the six months ended June 30, 2016; and (ii) three additional months of activity for the Black Oak operations acquired on April 1, 2016.

Operating Income (Loss)

We realized an operating loss of $10.55 million for the six months ended June 30, 2017, compared to an operating loss of $5.73 million for the six months ended June 30, 2016, an increase of $4.82 million or 84.1 percent.

Other Income (Expense)

Other expense for the six months ended June 30, 2017 was $930,000, compared to $3.20 million for the six months ended June 30, 2016, a decrease of $2.27 million or 71.0 percent. This decrease was primarily attributable to: (i) a $4.99 million gain on settlement of contingent consideration related to the Black Oak acquisition (see “Note 9 – Contingent Consideration Liability” for further information); (ii) a $4.43 million loss on fair market valuation of contingent consideration; (iii) an increase in loss on extinguishment of debt of $1.76 million, which was $2.68 million for the six months ended June 30, 2017, compared to $921,000 in the prior year period; (iv) an increase in amortization of debt discount of $814,000, which was $1.13 million for the six months ended June 30, 2017, compared to $313,000 in the prior year period; (v) a decrease in gain (loss) on fair market valuation of derivatives of $3.96 million, which was a gain of $2.60 million for the six months ended June 30, 2017, compared to a loss of $1.37 million in the prior year period; and (vi) a decrease in loss from derivatives issued with debt greater than debt carrying value of $488,000, which was zero for the six months ended June 30, 2017, compared to $488,000 in the prior year period.

Net Loss Attributable to Terra Tech Corp.

We incurred a net loss attributable to Terra Tech Corp. of $10.57 million, or $0.02 per share, for the six months ended June 30, 2017, compared to a net loss attributable to Terra Tech Corp. of $9.06 million, or $0.03 per share, for the six months ended June 30, 2016. The primary reasons for the increase were a decrease in revenue, and an increase in selling, general and administrative expenses during the six months ended June 30, 2017, compared to the prior year period.

Management will continue its efforts to lower operating expenses and increase revenue. We will continue to invest in further expanding our operations and a comprehensive marketing campaign with the goal of accelerating the education of potential clients and promoting our name and our products. Given the fact that most of the operating expenses are fixed or have a quasi-fixed character, management expects that, as revenue increases, those expenses, as a percentage of revenue, will significantly decrease. Nevertheless, there can be no assurance that we will be able to increase our revenues in succeeding quarters.

37
 
Table of Contents

 

DISCLOSURE ABOUT OFF-BALANCE SHEET ARRANGEMENTS

 

We do not have any transactions, agreements or other contractual arrangements that constitute off-balance sheet arrangements.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

Our “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section discusses our unaudited consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. These accounting policies are described in “Note 2 - Summary of Significant Accounting Policies” of the Notesnotes to Unaudited Consolidated Financial Statementsunaudited consolidated financial statements included in this report.

 

LIQUIDITY AND CAPITAL RESOURCES

 

We have never reported net income. We incurred net losses for the six months ended June 30, 2018 and 2017 and have an accumulated deficit of $83.44approximately $127.01 million as ofand $105.55 million at June 30, 2017, compared to an accumulated deficit of $72.87 million at2018 and December 31, 2016. 2017, respectively.

As of June 30, 2017,2018, we had working capital of $6.51$12.39 million, including $5.15 million of cash compared to a working capital deficit of $9.56$3.47 million, atincluding $5.45 million of cash as of December 31, 2016. At2017. Current assets were approximately 3.1 times current liabilities as of June 30, 2017, we had a cash balance of $9.13 million,2018, compared to a cash balanceapproximately 1.2 times current liabilities as of $9.75 million at December 31, 2016.2017.

 

We have not been able to generate sufficient cash from operating activities to fund our ongoing operations. Additional requirements for inventory will continue to increase. Prior to 2017, Black Oak had been purchasing inventory on a consignment basis. Accordingly, title did not pass to us until we ultimately sold the inventory. During 2017 the terms of our purchase of inventory changed with the various vendors we purchased from. The vendors required that title passes to us upon delivery to us. Accordingly, this increased our cash requirements for operational purposes as we are now required to pay with normal terms. Since our inception, we have raised capital through private sales of preferred stock, common stock, and debt securities. Our future success is dependent upon our ability to achieve profitable operations and generate cash from operating activities. There is no guarantee that we will be able to generate enough revenue and/or raise capital to support our operations.

 

In connection with the sale of the Company’s MediFarm LLC dispensary located at 1921 Western Ave., Las Vegas, NV 89102, the Company expects to generate net cash of approximately $6.25 million. Other than these proceeds, the Company does not expect the sale of MediFarm LLC to have a significant impact on liquidity.

We anticipate requiring additional capital for the commercial development of our subsidiaries. Black Oak,facilities. Blüm San Leandro and the Hegenberger facility, together, will require approximately $3.0$1.5 million in capital to complete. Construction for the completion of the packaging facility for Edible Garden will require approximately $1.2$0.8 million. The estimated construction budget for the development of the cultivation and production facilities under MediFarm II is approximately $2.0 million. Forever Green NV, LLC, a member of MediFarm II, has agreed to contribute approximately $750,000 in the form of debt to MediFarm II. We will be obligated to contribute the remaining amount.

37

Table of Contents

  

We will be required to raise additional funds through public or private financing, additional collaborative relationships or other arrangements until we are able to raise revenues to a point of positive cash flow. We believe our existing and available capital resources will be sufficient to satisfy our funding requirements through the secondfourth quarter of 2018. We are evaluating2020. However, we continue to evaluate various options to further reduce our cash requirements to operate at a reduced rate, as well as options to raise additional funds, including obtaining loans and selling common stock. In March 2018 we entered into a $40.0 million 2018 Master Security Purchase Agreement with an accredited investor. As of June 30, 2018, the Company has received $5.0 million under this agreement. There is no guarantee that we will be able to generate enough revenue and/or raise capital to support our operations, or if we are able to raise capital, that it will be available to us on acceptable terms, on an acceptable schedule, or at all.

38
Table of Contents

 

The issuance of additional securities may result in a significant dilution in the equity interests of our current stockholders. Obtaining loans, assuming these loans would be available, will increase our liabilities and future cash commitments. There is no assurance that we will be able to obtain further funds required for our continued operations or that additional financing will be available for use when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we will not be able to meet our other obligations as they become due and we will be forced to scale down or perhaps even cease our operations.

 

Operating Activities

 

Cash used in operating activities for the six months ended June 30, 20172018 was $7.15$9.87 million, compared to $3.30$7.15 million for the six months ended June 30, 2016,2017, an increase of $3.85$2.72 million, or 116.4approximately 38.1 percent. Increases in cash used in operating activities were primarily due to: (i) a $11.48 million net loss for the six months ended June 30, 2017, compared to a $9.32 million loss for the six months ended June 30, 2016, an increase of $2.16 million; (ii) a decrease in gain (loss) on fair market valuation of derivatives of $3.96 million, which was a gain of $2.60 million for the six months ended June 30, 2017, compared to a loss of $1.37 million in the prior year period; and (iii) a decrease in accounts payable and accrued expenses of $1.35 million. Decreases in cash used in operating activities were primarily due to: (i) an increase in net loss of $9.80 million; (ii) an increase of $5.18 million in loss on extinguishment of debtdebt; and (iii) a decrease of $1.76$1.97 million which was $2.68 million for the six months ended June 30, 2017, compared to $921,000 in the prior year period; and (ii) an increase in amortizationgain on fair value market valuation of debt discount of $814,000, which was $1.13 million for the six months ended June 30, 2017, compared to $313,000 in the prior year period.derivatives.

 

Investing Activities

 

Cash used in investing activities for the six months ended June 30, 20172018 was $1.04$8.46 million, compared to cash used in investing activities of $1.90$1.04 million for the six months ended June 30, 2016, a decrease2017, an increase of $864,000,$7.42 million, or 45.5716.4 percent. During the first six months of 2017,ended June 30, 2018, cash used in investing activities was primarily comprised of expenditures related to: (i) the construction of the San Leandro and Oakland facilities; and (ii) capital expenditures at Edible Garden in Belvidere, N.J.; and (iii) payment for acquisition of land in Santa Ana, California.

 

Financing Activities

 

Cash provided by financing activities for the six months ended June 30, 20172018 was $7.57$18.08 million, compared to $6.46$7.57 million for the six months ended June 30, 2016,2017, an increase of $1.11$10.51 million, or 17.2138.8 percent. CashThe increase in cash provided by financing activities for the six months ended June 30, 20172018 was primarily due to: (i) $6.00$9.0 million from the issuance of debt; (ii) $3.75a $2.09 million from the salepayment of common stock; partiallycontingent consideration; offset by (iii) payment of $2.09a $0.47 million increase in cash paid for the contingent consideration related to the Black Oak acquisition.

39
Table of Contents
debt discount.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKRISK..

 

Our primary market risks are attributable to fluctuations in commodity prices and interest rates. These fluctuations can affect revenues and cash flow from operating, investing and financing activities.

 

Commodity Price Risk

 

Our most significant market risk relates to fluctuations in marijuana prices. Management expects the prices of these commodities to remain volatile and unpredictable. As these prices decline or rise significantly, revenues and cash flow will also decline or rise significantly.

 
38
Table of Contents

Interest Rate Risk

 

As of June 30, 2017,2018, we had no outstanding variable-rate debt and $3.65$15.0 million of principal fixed-rate debt.

 

Credit Risk

 

Our exposure to non-payment or non-performance by our customers and counterparties presents a credit risk. Generally, non-payment or non-performance results from a customer’s or counterparty’s inability to satisfy obligations. We may also be exposed to credit risk due to the concentration of our customers in the medical marijuana industry, as our customers may be similarly affected by changes in regulatory and legal conditions in the states and municipalities in which we operate.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Under the supervision and with the participation of our management, our principal executive officer and our principal financial officer are responsible for conducting an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of the end of the fiscal year covered by this report.June 30, 2018. Disclosure controls and procedures means that the material information required to be included in our SEC reports is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms relating to our company, including any consolidating subsidiaries, and was made known to us by others within those entities, particularly during the period when this report was being prepared. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were not effective as of June 30, 2017.2018.

As of December 31, 2017, management assessed the effectiveness of our internal controls over financial reporting. Management concluded, as of the year ended December 31, 2017, that our internal controls and procedures were not effective to detect the inappropriate application of U.S. GAAP rules. Management concluded that our internal controls were adversely affected by deficiencies in the design or operation of our internal controls, which management considered to be material weaknesses. These material weaknesses include the following:

Risk Assessment – We did not have an effective risk assessment process. From a governance perspective, our formal process to identify, update and assess risks, including changes in our business practices that significantly impact our consolidated financial statements as well as the system of internal control over financial reporting was incomplete.

Control Environment – We did not maintain an effective control environment as evidenced by:

·

Lack of majority independent board members.

·

An insufficient number of personnel to adequately exercise appropriate oversight of accounting judgements and estimates.

Control Activities – We did not have control activities that were designed and operating effectively to identify and address all likely sources of material misstatements, including non-standard transactions. In addition, management review controls were not sufficient or in place to identify all potential accounting errors.

Information and Communications – We had not implemented appropriate information technology controls related to access rights for certain financial spreadsheets that are relevant to the preparation of the consolidated financial statements and our system of internal control over financial reporting. In addition, we did not implement the appropriate information technology disaster recovery controls in place to ensure the completeness of financial information surrounding revenues and inventory.

39
Table of Contents

Monitoring – We did not maintain effective monitoring of controls related to the financial close and reporting process. In addition, we did not maintain the appropriate level of review and remediation of internal control over financial reporting deficiencies throughout interim and annual financial periods.

The failure to implement and maintain proper and effective internal controls and disclosure controls could result in material weaknesses in our financial reporting, such as errors in our financial statements and in the accompanying footnote disclosures that could require restatements. Investors may lose confidence in our reported financial information and disclosure, which could negatively impact our stock price.

We do not expect that our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. Over time, controls may become inadequate because changes in conditions or deterioration in the degree of compliance with policies or procedures may occur. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Plan for Remediation of the Material Weaknesses

We are implementing and are continuing to implement a number of measures to address the material weaknesses identified. The remediation activities undertaken by the Company included the following:

·

Continuing to improve the control environment through (i) being staffed with sufficient number of personnel to address segregation of duties issues, ineffective controls and to perform control monitoring activities, (ii) increasing the level of GAAP knowledge by retaining additional technical accountants, (iii) implementing formal process to account for non-standard transactions, and (iv) implementing and formalizing management oversight of financial reporting at regular intervals;

·

Continuing to update the documentation of our internal control processes, including implementing formal risk assessment processes;

·

Implementing control activities that address relevant risks and assure that all transactions are subject to such control activities;

·

Ensure systems that impact financial information and disclosures have effective information technology controls;

·

Executing plan to increase number of independent directors to enhance corporate governance and Board composition;

·

Hiring of third party Sarbanes-Oxley consultants to assist management with the implementation of additional control activities;

·

Implementing plan to increase oversight and review of ad hoc spreadsheets while also working to reduce their use; and

·

Designation of VP Director of Internal Controls and hiring of sufficient personnel to effectively implement changes to remediate the material weakness and control over financial reporting.

There are no assurances that the measures we have taken to date, or any measures we may take in the future, will be sufficient to remediate the material weaknesses we have identified or avoid potential future material weaknesses.

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal controlscontrol over financial reporting during(as defined in Rules 13a-15(f) and 15d-15(f) under the most recently completed fiscal quarterExchange Act) as of June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.reporting, except as disclosed in Remediation of Material Weakness above.

 
 
40
 
Table of Contents

 

PART II OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

WeThe Company is the subject of lawsuits and claims arising in the ordinary course of business from time to time. The Company reviews any such legal proceedings and claims on an ongoing basis and follows appropriate accounting guidance when making accrual and disclosure decisions. The Company establishes accruals for those contingencies where the incurrence of a loss is probable and can be reasonably estimated, and it discloses the amount accrued and the amount of a reasonably possible loss in excess of the amount accrued if such disclosure is necessary for the Company’s financial statements to not be misleading. To estimate whether a loss contingency should be accrued by a charge to income, the Company evaluates, among other factors, the degree of probability of an unfavorable outcome and the ability to make a reasonable estimate of the amount of the loss. The Company does not record liabilities when the likelihood that the liability has been incurred is probable, but the amount cannot be reasonably estimated. Based upon present information, the Company determined that there were no matters that required an accrual as of June 30, 2018 nor were there any asserted or unasserted material claims for which material losses are reasonably possible.

On April 11, 2018, the Company filed a lawsuit in the United States District Court, Central District of California against Kenneth Vande Vrede, Michael Vande Vrede, Steven Vande Vrede, Daniel Vande Vrede, Greda Vande Vrede, Beverly Willekes, Brian Vande Vrede, Gro-Rite, Inc. (“Gro-Rite”) and Naturally Beautiful Plant Products, LLC (“Naturally Beautiful”) alleging breach of contract, breach of fiduciary duties, conversion, fraud, breach of covenant of good faith and fair dealing, misappropriation of trade secrets, and conspiracy related to, among other things, the Share Exchange Agreement, dated as of April 24, 2013 among the Company, the Company’s wholly-owned subsidiary, Edible Garden Corp. (“Edible Garden”), and the individual defendants (the “Share Exchange Agreement”). The Company is seeking monetary damages, including attorneys’ fees and expenses, return of shares of the Company’s common stock issued to the individual defendants under the Share Exchange Agreement, return of stock options issued to the individual defendants, and return of the Company’s intellectual property.

On April 10, 2018, Gro-Rite, Naturally Beautiful and Whitetown Realty (“Whitetown Realty” and collectively, the “Whitetown Realty Plaintiffs”) filed a lawsuit in the Superior Court of New Jersey Law Division, Morris County against the Company and Edible Garden alleging, among other things, that Edible Garden owes certain amounts to Gro-Rite under a Marketing and Distribution Agreement between Edible Garden and Gro-Rite, dated May 7, 2013, and Naturally Beautiful under a Marketing and Distribution Agreement between Edible Garden and Naturally Beautiful, dated May 13, 2013 (collectively, the “Marketing and Distribution Agreements”), and that Edible Garden owes certain amounts to Whitetown Realty under the Lease between Whitetown Realty and Edible Garden, dated January 1, 2015 (the “Lease”). The Whitetown Realty Plaintiffs are seeking, among other things, compensatory damages for the amounts claimed are owed and attorneys’ fees and costs. The Company believes that Edible Garden does not currently subjectowe any payments under the Marketing and Distribution Agreements or the Lease. The Company disputes the Whitetown Realty Plaintiffs’ allegations in the lawsuit and intends to vigorously defend itself. Accordingly, on May 18, 2018, the Company and Edible Garden filed an answer denying the allegations of the Whitetown Realty plaintiffs.  In that same pleading, Edible Garden filed a counterclaim against Naturally Beautiful and Gro-Rite asserting claims for breach of contract, breach of the implied covenant of good faith and fair dealing, unjust enrichment, trademark infringement/unfair competition, and tortious interference with contractual relations.  Edible Garden also filed a third-party complaint against previously unidentified defendants John Doe Entities 1-10 and John Doe Individuals 1-10 arising from the wrongful misappropriation and pirating of electricity from the Edible Garden facility located at 283 Route 519, Belvidere, New Jersey.  That third-party complaint alleges claims for unjust enrichment, tortious interference with contractual relations and conversion.  On June 8, 2018, Edible Garden filed an amended counterclaim adding a count for conversion against Naturally Beautiful and Gro-Rite.  On June 12, 2018, Edible Garden Corp. filed an amended third-party complaint adding Gerda Vande Vrede as a named third-party defendant.  On June 13, 2018, Gro-Rite and Naturally Beautiful filed an answer to Edible Garden’s amended counterclaim and Gerda Vande Vrede filed an answer to Edible Garden’s amended third-party complaint denying the allegations asserted against them.  No counterclaims, crossclaims or fourth party complaints were filed on behalf of Gerda Vande Vrede, Naturally Beautiful or Gro-Rite.

On April 13, 2018, Edible Garden Corp. filed a lawsuit in the Superior Court of New Jersey Chancery Division, Warren County against Whitetown Realty in response to a letter from a law firm representing Whitetown Realty alleging Edible Garden was in default of the Lease. Edible Garden is seeking declaratory and equitable relief to prevent Whitetown Realty from terminating the Lease and for attorneys’ fees and costs. The Company believes that Edible Garden has made all payments due to Whitetown Realty under the Lease and maintains Edible Garden is not in default of the Lease. On April 23, 2018, by order of the assignment judge of Warren County, the lawsuit was transferred to Morris County and consolidated with the April 10, 2018 lawsuit previously filed by Gro-Rite, Naturally Beautiful and Whitetown Realty in the Superior Court of New Jersey, Law Division, Morris County.  On June 13, 2018, Whitetown Realty filed its answer to the Edible Garden Complaint.  In that answer, Whitetown Realty denies that Edible Garden is entitled to the declaratory and equitable relief that Edible Garden requested.  No counterclaim was filed by Whitetown Realty.

41
Table of Contents

On April 11, 2018, Kenneth Vande Vrede, Michael Vande Vrede and Steven Vande Vrede (collectively, the “Vande Vrede Brothers”) filed a lawsuit in the Superior Court of New Jersey Law Division, Warren County against the Company and Edible Garden alleging, among other things, that the Company and Edible Garden improperly suspended the Vande Vrede Brothers from their positions with the Company and Edible Garden. The Vande Vrede Brothers were seeking, among other things, a declaratory judgment that they did not violate their fiduciary duties owed to the Company or Edible Garden and reinstating the Vande Vrede Brothers to their status with the Company and Edible Garden prior to their suspensions and attorneys’ fees and costs. The original complaint in this matter was never served, and on June 12, 2018, the Vande Vrede Brothers, and now David Vande Vrede, Daniel Vande Vrede, Beverly Willekes, and Whitetown Realty filed an amended complaint against Terra Tech, Edible Garden, Derek Peterson, Michael James, and Michael Nahass.  The Company filed a pre-answer motion to dismiss the amended complaint, arguing that any legal proceedings. of the plaintiffs’ claims that relate to the Share Exchange Agreement, belong in the already existing lawsuit in California, and any of the plaintiffs’ claims that relate to the lease, belong in the already existing lawsuits in New Jersey.  The Company disputes the Vande Vredes’ allegations in the lawsuit and intends to vigorously defend itself.

From time to time, we also may become subject to other litigation or proceedings in connection with our business, as either a plaintiff or defendant. There are no such pending legal proceedings to which we are a party that, in the opinion of management, is likely to have a material adverse effect on our business, financial condition or results of operations.

 

ITEM 1A. RISK FACTORS.

 

There have been no material changes to the risk factors disclosed in Part I, Item 1A, “Risk Factors”, of our Annual Report on Form 10-K for the year ended December 31, 2016.2017, except for the risk factor noted below. Please refer to that section for disclosures regarding the risk and uncertainties relating to our business.

California Phase-In of Laboratory Testing Requirements

Beginning July 1, 2018, cannabis goods must meet all statutory and regulatory requirements. A licensee can only sell cannabis goods that have been tested by a licensed testing laboratory and have passed all statutory and regulatory testing requirements. In order to be sold, cannabis goods harvested or manufactured prior to January 1, 2018, must be tested by a licensed testing laboratory and must comply with all testing requirements in section 5715 of the Bureau of Cannabis Control (“BCC”) regulations. Cannabis goods that do not meet all statutory and regulatory requirements must be destroyed in accordance with the rules pertaining to destruction. See “Note 3 – Concentrations of Business and Credit Risk” for additional information on California laboratory testing requirements.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

None.

 

ITEM 5. OTHER INFORMATION.

 

None.

 
4142
 
Table of Contents

  

ITEM 6. EXHIBITS.EXHIBITS.

 

Exhibit

 

Description

 

3.1

 

Certificate of Amendment to Certificate of Designation of Series B Preferred Stock,Amended Bylaws, dated July 26, 2017 (1)June 20, 2018 *

 

4.1

 

Form of 12%7.5% Senior Convertible Promissory Note (2)(1)

 

4.2

 

Form of 12% SeniorAmendment No. 1 to Convertible Promissory Note (3)

10.1

Operations and Asset Management Agreement dated March 31, 2016, by and among Platinum Standard, LLC, Black Oak Gallery, and Terra Tech Corp. (4)(2)

 

10.24.3

 

Form of Security Agreement, dated as of June 23, 2017 Amendment No. 1 to Convertible Promissory Note (2)

10.3

Form of Security Agreement, dated as of February 22, 2017 (3)

 

31.1

 

Certification of Derek Peterson, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *

 

31.2

 

Certification of Michael C. James, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. *

 

32.1

 

Certification of Derek Peterson, Chief Executive Officer, pursuant to Sections 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350. *

 

32.2

 

Certification of Michael C. James, Chief Financial Officer, pursuant to Sections 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350. *

 

101.INS

 

XBRL Instance Document *

 

101.SCH

 

XBRL Taxonomy Extension Schema Document *

 

101.CAL

 

XBRL Taxonomy Extension Calculations Linkbase Document *

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document *

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document *

 

101.PRE

 

XBRL Taxonomy Presentation Linkbase Document *

______________

* Filed herewith

__________________

*Filed herewith

(1)Incorporated by reference to Current Report on Form 8-K filed with the SEC on July 26, 2017.June 8, 2018.
(2)Incorporated by reference to Current Report on Form 8-K filed with the SEC on June 23, 2017.
(3)Incorporated by reference to Current Report on Form 8-K filed with the SEC on February 22, 2017.
(4)Incorporated by reference to Quarterly Report on Form 10-Q filed with the SEC on May 12, 2016.2, 2018.

 

 
4243
 
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



 

TERRA TECH CORP.

Date: August 8, 20179, 2018

By:

/s/ Michael C. James

Michael C. James

Chief Financial Officer Chief

(Principal Accounting Officer and

Principal Financial Officer)

 

43

44